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PREFACE 
 
 
This thesis comprises work performed at the Department of Functional Neuroanatomy and Biomarkers, 
NeuroSearch AS in the period from September 2004 to January 2005. Part of the study period September to 
December 2005 was spent at the Laboratory of Stress Neurobiology at the Cincinnati University, Genome 
Research Institute.  
 
During the little more than 1 year and 3 months I have worked on this project I have become familiar with, 
different areas of pharmacology, molecular physiology, histology and neuroanatomy. 
The project has evolved from being a purely pharmacological project, to cross over borders into the areas of 
histology and physiology. During the project I have had the pleasure and challenge of learning a wide array of 
techniques including: radioimmunoassay, immunocytochemistry, in situ hybridization and neurotracing techniques.  
 
In order to lawfully conduct animal procedures I was required by Danish law to take a 3 week course in laboratory 
animal science at the Royal Danish Veterinary and Agricultural University (KVL), this was done in January of 2005. 
The project has during the entire period been carried out as an integrated part of Neurosearch’s anxiety research, 
with special emphasis on GABA inhibitory regulation of the hypothalamic pituitary adrenal axis (HPA axis). 
 
The work done in the thesis has resulted in one published paper; the article has been accepted by The European 
journal of Pharmacology (Mikkelsen et al., 2005) presented in appendix E. I have also had the pleasure of 
presenting my work as a poster at the Society of Neuroscience annual meeting in November 2005. The abstract 
from the meeting is presented in appendix D. 
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Abstract  
 
Previous studies have demonstrated that classical benzodiazepines decrease hypothalamic–pituitary–adrenocortical 
cortex (HPA) axis activity. Paradoxically, high doses of benzodiazepines also stimulate basal circulating 
corticosterone levels in some conditions. Because benzodiazepine agonists display little selectivity to any of the α 
subtypes of the γ-amino butyric acid GABAA receptor to which they bind, we propose that the unequivocal results 
are due to an a subtype-dependent modulation of the hypothalamic–pituitary–adrenocortical cortex axis output. To 
test this, basal hormonal output and induction of FOS in the hypothalamic paraventricular nucleus were measured 
after administration of various benzodiazepine ligands in mice. Zolpidem, a selective α1 subtype agonist, produced 
a very strong increase in plasma adrenocorticotropic hormone and corticosterone  
The non-selective full agonist’s diazepam and zopiclone induced a lower increase in circulating corticosterone than 
after zolpidem. In contrast, the α2,3,5 selective benzodiazepine agonist and α1 antagonist L-838,417 had no effect on 
corticosterone levels. Strong induction of FOS in the paraventricular nucleus was found in response to zolpidem, 
diazepam, and zopiclone, but not L-838,417. Finally, pre-administration of L-838,417 prior to zolpidem strongly 
inhibited the effect of zolpidem on corticosterone. Likewise, the non-selective agonist’s diazepam and zopiclone at 
a dose that alone had no effect on corticosterone also inhibited the effect of zolpidem. Taken together, these 
results suggest that benzodiazepine ligands modulate the hypothalamic–pituitary–adrenocortical axis through partly 
opposite mechanisms; and that the net effect is dependent on the composition of the GABAA receptor subunits to 
which they bind. 
In order to further explain the biological mechanism by which the different benzodiazepins activate the 
hypothalamic–pituitary–adrenocortical axis, we performed in situ hybridization to clarify the GABAA subunit 
composition in the paraventricular nucleus and sub paraventricular area, we show in agreement with the available 
literature that the paraventricular nucleus is comprised of neurons with the α2 phenotype. We also find that the sub 
paraventricular nucleus is made up of neurons with the α1 phenotype this has not been shown elsewhere.   
In this study we also conclude that the neurons in the paraventricular nucleus that are activated after zolpidem 
administration do not co-express oxytocin to any significant degree. 
The study also makes an attempt to map afferent connection to the paraventricular nucleus, this is done using 
Cholera toxin subunit B as a retrograde tracer. We focuses the projections origination in the bed nucleus stria 
terminalis, and in agreement with the available literature find that the bed nucleus stria terminalis has numerous 
projections to the paraventricular nucleus, we also find that most of these projections originate in either the lateral 
division or in the medial division, anterior part of the bed nucleus stria terminalis.  
 
 
 
GABA NEUROCIRCUITS CONTROLLING  
THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS 
 
                            
    
− iii − 
JANUARY 2006 
 NEUROSEARCH 
Resume 
 
 
Tidligere studier har vist at terapeutiske doser af de klassiske benzodiazepiner hæmmer aktiviteten af 
hypothalamus-hypofyse-binyrebark aksen. Pardoksalt er det dog at høje doser af benzodiazepiner samtidigt 
stimulere produktionen af corticosterone. De klassiske benzodiazepiner udviser ingen selektivitet over for de 
forskellige α subunits, der er en del af γ-amino butyric acid GABAA receptoren. Vores hypotese er at, de i 
litteraturen modsigende resultater skyldes en α subunit afhængig modulation af hypotalamus-hypofyse-binyrebark 
aksens produktion af corticosterone (cortisol i mennesker). For at teste dette blev plasma hormon niveauerne 
(ACTH og corticosterone), samt induktion af FOS i den paraventrikulære hypothalamiske kerne målt i mus, efter 
dosering af benzodiazepiner med forskellig affinitet for α subunits. 
Zolpidem som er en α1 selektiv agonist, var årsag til en kraftig stigning i plasma corticosterone hos mus. De to non-
selektive agonister diazepam og zopiclone induerede også en stigning i plasma cortocosterone, denne var dog for 
både effekt og potens lavere end efter behandling med zolpidem.  I skarp kontrast til disse resultater inducerede 
den α2,3,5 selective benzodiazepin agonist og α1 antagonist L-838,417 ingen effekt på hypotalamus-hypofyse-
binyrebark aksen. Svarende til disse resultater, sås en kraftig induktion af FOS i den paraventrikulære 
hypothalamiske kerne efter behandling med zolpidem, diazepam og zopiclone men ikke efter L-838,417.  
Ved at forbehandle dyrene med L-838,417 før indgift af zolpidem var vi i stand til kraftigt at hæmme zolpidems 
effekt på corticosterone. Det samme var tilfældet hvis vi forbehandlede med enten diazepam eller zopiclone i doser 
der i dem selv ikke stimulere et corticosterone respons. 
Dette har ledt til en hypotese hvor vi foreslår at benzodiazepiner modulere hypotalamus-hypofyse-binyrebark aksen 
via en modsat rettet mekanisme hvor netto effekten afhænger af sammensætningen af GABAA receptorens 
underenheder. Vi fastslår også i dette studie at de neuroner, der er aktiveret i den paraventrikulære hypothalamiske 
kerne efter behandling med zolpidem, og derfor er FOS positive ikke samtidigt udtrykker oxytocin. 
For at forklare den biologiske mekanisme i nærmere detaljer, var det nødvendigt at bestemme i hvordan GABAA α 
enheder var udtrykt i den paraventrikulære hypothalamiske kerne samt de omkringliggende områder, dette blev 
gjort ved at benytte in situ hybridzering. Vi bestemte i overensstemmelse med litteraturen at neuronerne i PVN 
udtrykker GABAA α2 noget nyt er at vi her viser at neuronerne i det sub i paraventrikulære hypothalamiske kerne 
område udtrykker α1. 
I en del af studiet forsøger vi at kortlægge afferente nervebaner til PVN, i studiet benytter vi os af den retrograde 
tracer cholera toxin subunit B. I studiet bliver der fokuseret på nervebaner der har deres udspring i bed nucleus 
stria terminalis, resultaterne viser at der er adskillige nerveceller i bed nucleus stria terminalis med projektioner til 
den paraventrikulære hypothalamiske kerne, dette er i god overensstemmelse med hvad der findes i litteraturen, vi 
viser dog at de fleste af disse projektioner oprinder i enten den laterale eller mediale, anterior del af bed nucleus 
stria terminalis.  
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ABBREVIATIONS  
 
AC  Anterior commissure 
ACA  Anterior commissure, anterior part 
ACTH  Adrenocorticotrophic hormone 
AVP  Arginine vasopressin 
BNST  Bed nucleus of the stria terminalis 
BSTIA   Bed nucleus of the stria terminalis, intraamygdaloid division  
BSTL   Bed nucleus of the stria terminalis, lateral division  
BSTLD  Bed nucleus of the stria terminalis, lateral division, dorsal part  
BSTLI   Bed nucleus of the stria terminalis, lateral division, intermediate part 
BSTLJ   Bed nucleus of the stria terminalis, lateral division, juxtacapsular part 
BSTLP   Bed nucleus of the stria terminalis, lateral division, posterior part  
BSTLV  Bed nucleus of the stria terminalis, lateral division, ventral part  
BSTMA  Bed nucleus of the stria terminalis, medial division, anterior part  
BSTMPI  Bed nucleus of the stria terminalis, medial division, posterointermediate part  
BSTMPL  Bed nucleus of the stria terminalis, medial division, posterolateral part 
BSTMPM  Bed nucleus of the stria terminalis, medial division, posteromedial part  
BSTMV  Bed nucleus of the stria terminalis, medial division, ventral part  
BSTS  Bed nucleus of stria terminalis, supracapsular part  
ChB  Cholera toxin subunit B 
CRH  Corticotrophin releasing hormone 
DEPC  Diethylpyrocarbonate 
GABA  γ aminobutyric acid 
GABAA  γ aminobutyric acid receptor A 
GAD  Glutamic acid decarboxylase 
GLU  Glutamic acid 
GR  Glucocorticoid receptor 
HPA axis Hypothalamic-pituitary-adrenal axis 
ICC  Immunocytochemistry 
I.P.  Intraperitoneal 
KPBS  Potassium phosphate buffered saline   
LH  Luteinizing hormone 
LV  Lateral ventricle  
MNOP  Median preoptic nucleus 
MR  Mineralocorticoid receptor 
OX  Optic chiasm 
PBS  Phosphat buffered saline 
POMC  Pro-opiomelanocortin 
SCC  Podium cacodylate buffer 
SCN  Suprachiasmatic Nucleus 
SubPVN Sub paraventricular nucleus  
VIP  Prolactine releasing hormone releasing factor 
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1. INTRODUCTION 
 
Stress is a phenomenon we see all around us, but seemingly the term is too well known and too little understood. 
Exposure to acute or chronic stress will induce immediate as well as long term changes in the central nervous 
system (CNS).  During the last 30 years, it has become increasingly clear that stress serves as one of the main 
triggers for psychiatric as well as non-psychiatric disorders, including depression, anxiety, psychosis, drug abuse and 
dementia (Able, 2005).  
Thus the topic of stress and understanding the underlying biological principles governing the stress response is of 
the outmost importance to the scientific and medical community. 
 
This thesis will focus on the role of the inhibitory neurotransmitter γ-aminobuturic acid, receptor A (GABAA) and 
the receptors role in controlling specific neurocircuits of the hypothalamic pituitary adrenal cortical axis (HPA axis) 
which is a key component of the biological stress response.  
 
GABA is the major inhibitory neurotransmitter in the mammalian brain and GABA exerts its effect through two 
distinct receptor types the GABAA and GABAB receptors, this thesis will focus on the GABAA receptor.  
The GABAA receptor is the site of action of benzodiazepines in the brain. Multiple isoforms of GABAA receptor 
exist; each receptor is comprised of a pentameric complex, formed by the co-assembly of subunits selected from 16 
genes (α1-6, β1-3, γ1-3, δ, ε, π, and θ) surrounding a central chloride ion-channel (Sieghart, 1995). Agonist activation of 
the GABAA receptor is augmented by the anxiolytic benzodiazepine ligands, causing a parallel shift of the GABA 
concentration-response curve (Barnard et al., 1998; Sieghart, 1995). The α subunit isoform present within an 
individual GABAA receptor subtype is the primary determinant of benzodiazepine ligand recognition (Fleck, 2002; 
Mehta and Ticku, 1999; Pritchett and Seeburg, 1990). GABAA receptors containing α1, α2, α3, or α5 together with β, 
and a γ2 subunit are all recognised by the classical benzodiazepines. Selective benzodiazepines as well as other drugs 
distinguish the GABAA receptors on the basis of their α subunit composition. For example, the sedative-hypnotic 
imidazolpyridine zolpidem has higher affinity for α1 than  α2, α3, or α5-containing GABAA receptors (Squires et al., 
1979). More recently new anxiolytic compounds with subtype selection for α2, α3, and α5 over α1 containing 
GABAA receptors such as L-838,417 have been developed (McKernan et al., 2000). It is therefore plausible that 
distinct α subtype-specific GABAA receptors mediate various effects of classical benzodiazepines. 
 
Disturbances in the hypothalamic–pituitary–adrenocortical (HPA) axis are well known in human depression and 
anxiety, as well as in experimental animal models of anxiety and depression (Arborelius et al., 1999; Holsboer, 
2000; Jensen et al., 2001; Van de Kar and Blair, 1999). The abnormal hypersecretion of cortisol that occurs in a 
variety of psychiatric disorders including major depression, sleep disturbances, and anxiety is suppressed by 
administration of benzodiazepines (De Boer et al., 1990). Neurons in the medial parvocellular part of the 
hypothalamic paraventricular nucleus contain corticotrophin-releasing hormone (CRH), and these neurons 
integrate excitatory and inhibitory signals and behavioural responses to stress into appropriate secretion of CRH 
that leads to adrenocorticotropic hormone (ACTH) release to the general circulation (Van de Kar and Blair, 1999; 
Carrasco and Van de Kar, 2003). GABA is essential as a negative regulator of neuronal  excitability in the 
paraventricular nucleus, thus mediating the amplitude and the duration of the stress response (Kovacs et al., 2004). 
GABA is also contained in neurons comprised in the negative feedback loop to the paraventricular nucleus 
(Bowers et al., 1998), and it is plausible that GABAA receptors may act on converging projections to the 
paraventricular nucleus. GABAergic afferents in the paraventricular nucleus originating from a number of forebrain 
areas have been reported and ultrastructural studies have shown that GABAergic axons, to a large extent, terminate 
on CRH neurons (Sawchenko et al., 1996; Miklos and Kovacs, 2002), and in situ hybridisation and in vitro 
autoradiography have detected α1, α2, and α3 subtypes in the paraventricular nucleus (Cullinan, 2000; Duncan et al., 
1995; Fenelon et al., 1995). 
The role of benzodiazepines on basal corticosteroid release is complex, and even though it has been extensively 
studied over the last three decades, there is still a lot of controversy in the literature. Benzodiazepines have, under 
basal conditions, been shown to stimulate (Vargas et al., 2001; Le et al., 1979; Calogero et al., 1990), to inhibit 
(Owens et al., 1989; Pivac and Pericic, 1993), and to be ineffective (Matheson et al., 1988). The state of the animal 
under which these drugs are tested should be considered 
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with special care, because benzodiazepines interact with stress-related behaviours and cause a dose- dependent 
inhibition of stress-induced rise in corticosteroid levels (De Souza, 1990), for review). In addition, the effect of 
acute benzodiazepines on basal corticosterone levels might be related to several factors such as dose, compound 
and gender of the animal (Wilson et al., 1996), and these features might underlie the unequivocal results. In 
agreement with the literature, we show here that doses of diazepam higher than those producing anxiolytic effects 
increase corticosterone levels in mouse blood (Lakic et al., 1986; Kalman et al., 1997). We propose that the 
conflicting results reported earlier may also be a consequence of the net effect of non-selective benzodiazepines on 
the various GABAA receptor α subtypes. In order to address this issue, the responsiveness of the murine HPA axis 
output was examined after acute and combined treatments with a number of benzodiazepine receptor modulators 
specific for the α1 and/or α2,3,5 containing GABAA receptors. In addition, we used induction of FOS as a marker to 
identify the level of activation in the paraventricular nucleus after acute administration of benzodiazepine ligands. 
After having established that neurons in the PVN expressed FOS after administration of benzodiazepines, we 
made an effort to identify the phenotype of the FOS expressing neurons, utilizing double immunocytochemical 
labelling for FOS and oxytocin.  
The afferent projections to the PVN were also investigated; this was done using retrograde tracing techniques, with 
a special emphasis on the neurocircuits originating in the Bed Nucleus Stria Terminalis, the results obtained in 
these studies are in good agreement with the available literature (Herman et al., 2002; Ninan, 1999).   
We also made attempts to determine, whether or not the PVN projecting neurons in the Bed Nucleus Stria 
Terminalis expressed GAD65 m-RNA and therefore could be classified as being GABAergic.  
This was done using a labour intensive novel histological technique; more specifically a combination of in situ 
hybridization and immunocytochemistry, this last part of the project was carried out at the Genome Research 
Institute, University of Cincinnati, in close collaboration with Dr. James P. Herman.  
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1.1. SUMMARY OF THE PROJECT AIMS:  
  
• Investigate why high concentrations of benzodiazepines increase the basal level of corticosterone in mice.  
 
• Do neurons containing the GABAA receptor inhibit or activate the HPA axis, and what role do the 
different α subunits play?  
 
• Where in the brain do the different benzodiazepine ligands exert their effect.  
 
• What type of neurons is activated in the PVN?   
 
• To map afferent projections to the PVN and relate these to GABAergic neurons with emphasis on the 
BNST. 
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2. BACKGROUND THEORY  
 
2.1.1. GABAERGIC NEUROTRANSMISSION 
γ-aminobutyric acid (GABA) is widely found in both vertebrates and invertebrates and in both neuronal and non-
neuronal tissues. It was first identified as the neurotransmitter for an inhibitory neuromuscular junction in the 
walking leg of the lobster. Since its discovery over 50 years ago, numerous biochemical and neurophysical 
observations have been made about brain GABA and GABA-systems that make a strong case for its role as a 
neurotransmitter in the mammalian brain. (Cooper et al., 2003). 
 
GABA is synthesised from glutamate by the enzyme glutamic acid decarboxylase (GAD). It is stored in vesicles 
within the synaptic terminal of neurons. When an action potential travels down the axon and reaches the synaptic 
terminal, calcium channels are activated, resulting in calcium influx. This leads to fusion of the neurotransmitter-
containing vesicles with the cell membrane and release of the neurotransmitter, in this case GABA, into the 
synaptic cleft. Then GABA diffuses across the synaptic gap and binds to its receptor. GABA receptors are of two 
types, ionotropic (GABAA) or metabotropic (GABAB), and their activation leads to hyperpolarization of the 
postsynaptic membrane and a decrease in the excitability of the cell. The response is terminated by desensitization 
of the receptors and by enzymatic degradation or transport of GABA from the synapse into the presynaptic 
terminal or surrounding glial cells. The latter is achieved through specific transporter proteins referred to as GABA 
transporters. Once taken up into a cell, two potential fates await it. The GABA can be taken up into mitochondria 
and metabolized to succinic semialdehyde (by GABA transaminase), and then to succinic acid, and enter the 
tricarboxylic acid pathway. This is referred to as the GABA shunt. Alternatively, in the presynaptic terminal, it can 
be recycled into synaptic vesicles and, thereby, made available for subsequent release. 
 
 
Figure 1 “A schematic presentation of the vertebrate GABAergic synapse. GABA (filled circles) is generated from glutamate by glutamic 
acid decarboxylase (GAD). When released from presynaptic vesicles into the synaptic cleft, it diffuses across and binds to postsynaptic 
GABAA and GABAB receptors. It may also bind to presynaptic GABAB receptors. GABA is removed from the synaptic cleft into 
surrounding glial cells or the presynaptic terminal by GABA transporters. It is directly recycled into synaptic vesicles or taken up by 
mitochondria, converted by GABA transaminase (filled triangle)” (Creigton, 1999) 
 
Like other neurotransmitters GABA and its biosynthetic enzyme glutamine acid decarboxylase GAD, have a 
discrete non-uniform distribution through out the mammalian brain.  
Storage of GABA can be demonstrated in selected synaptosomal populations and the vesicular GABA transporter 
has been cloned and sequenced (Cooper and Bloom, 2003). 
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Release of endogenous or radioactive labelled GABA can be exogenously accumulated; GABA release can be 
evoked by appropriate experimental conditions. The presence of GABA-containing neurons has been mapped out 
using in situ hybridization for GAD mRNA and immunocytochemical detection of GAD. The most compelling 
proof, that GABA is a neurotransmitter in the brain, is that intracellular recording studies have shown that 
synthetic GABA causes a hyperpolarization of neurons similar to that evoked by naturally occurring transmitter 
substances, and that these inhibitory actions of synthetic GABA and GABA-containing pathways can be 
antagonized by drugs selective for the GABA receptor, such as bicuculline. (Decavel and Van den Pol, 1990). 
Three primary enzymes are involved in the catabolism of GABA before its final metabolite succinate enters the 
Krebs cycle. The relative activity of enzymes involved in the degradation of GABA suggests that they play only a 
minor role in the termination of the action of GABA. 
Figure 2 outlines the metabolism of GABA and its relationship to the Krebs cycle and carbohydrate metabolism. 
GABA is formed by the α-decarboxylation of L-glutamic acid, a reaction catalyzed by GAD, an enzyme that 
occurs uniquely in the mammalian CNS and retinal tissue. The precursor of GABA, L-glutamic acid, can be 
formed from α-oxoglutarate by transamination or reaction with ammonia. GABA is intimately related to the 
oxidative metabolism of carbohydrates in the CNS by means of a “shunt” involving its production from glutamate, 
its transanimation with α-oxoflutarate by GABA-α-oxoglutarate transaminase (GABA-T) yielding succinic 
semialdehyde and regeneration GLU, and finally its entry into the Krebs cycle as succinic acid via oxidation of 
succinic semialdehyde dehydrogenase. In essence then the shunt bypasses the normal oxidative metabolism 
involving the enzymes α-oxoglutarate dehydrogenase and succinyl thiokinase.  
From a metabolic standpoint the significance of the shunt is unknown; energetically, at least it is less efficient than 
direct oxidation through the Krebs cycle. The most common precursor of GABA formation is glucose, although 
pyrovate can also act as a precursor. (Cooper et al., 2003). 
 
 
Figure 2 “GAD catalyzes the formation of GABA from glutamic acid. The synthesis of GABA is linked to the Krebs cycle. GAD requires 
vitamin B6 (pyridoxal phosphate) as a cofactor, which can be used to regulate the levels of GABA. GABA can be metabolized by a 
transamination reaction with α-ketoglutarate, catalyzed by GABA-transaminase. Compounds such as the competitive GAD inhibitor 
allylglycine, inhibit GABA formation and cause convulsions due to the lack of GABA activity”(Messer, 2005) . 
 
Glutamic acid decarboxylase (GAD) is the only synthetic enzyme responsible for the conversation of L-glutamic 
acid to GABA and the reaction is irreversible. In mammals this relatively specific decarboxylase is found primarily 
in the CNS, where it occurs in high concentrations in the gray matter. In general the localization of this enzyme in 
mammals correlates quite well with the GABA content (Cooper et al., 2003). The brain enzyme has been purified 
to homogeneity and its properties have been studied in detail. It has a pH optimum of about 6.5 and requires 
pyridoxal phosphatate (vitamin B6) as a coenzyme. This purified enzyme is inhibited by structural analogs of Glu, 
carbonyl (pyridoxal phosphate [PLP] traping, agents). 
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Two isoforms of GAD have been identified which are encoded by two distinct genes. These two isoforms are 
designated GAD65 and GAD67 in accordant with their molecular weight. GAD65 and GAD67 differ in amino acid 
sequence antigenicity, cellular and subcellular location (Cooper et al., 2003) .  
 
2.1.2. GABAA RECEPTOR BIOLOGY 
 
GABA is as mentioned above the predominant inhibitory neurotransmitter in the mammalian central nervous 
system (CNS), with 30 % of all synapses classified as GABAergic. The GABA signal is transmitted by a family of 
synaptic and extra synaptic hetero-oligomeric proteins referred to as the GABAA receptors. 
When GABA binds to the GABAA receptor it acts by inducing conformational changes of the receptor, which 
increases the permeability of the central pore to chloride ions. The resulting chloride flux hyperpolarizes the 
neuron, thereby reducing is excitability and producing a general inhibitory effect on neural activity (Nutt and 
Malizia, 2001). 
 
Studies of the GABAA receptors molecular biology, done primarily using CDNA libraries have shown, that the 
GABAA receptor is assembled from 19 related genes. These are denoted as 6α, 4β, 3γ, 1δ, 1ε, 1π and 3ρ, the 
expressed proteins all weigh about ~50.000 Daltons, and each carry 4 transmembrane hydrophobic segments 
(TM1-4) (Barnard et al., 1998). 
The GABAA receptor found in the central nervous system is assembled primarily from the α1-6 and the β1-4 and 
one more of the γ, δ or ε subunits types. The most likely stoichiometry of GABAA receptor subunits in the CNS is 
2α, 2β and 1γ subunits (Tretter et al., 1997; Sieghart et al., 1999), arranged as a γ-β-α-β-α pentamer. The major 
part 60% of GABAA receptor isoforms in the adult mammalian brain consists of α1,β2, and γ2 subunits. Receptors 
with the α2 or α3 configuration constitute approximately 10- 20 % of the GABAA receptors in the brain. 
In contrast, most other combinations are rarely expressed or have a unique anatomical distribution and it is 
uncertain if they exist. For example the α4 subunit is concentrated in the thalamus and the hippocampal dentate 
gyrus. The α5 subunit is primarily expressed in the hippocampal pyramidal cells, while α6 m-RNA is restricted to 
cerbellar granule cells. Additional the π subunit is abundant in the uterus but is virtual absent in the brain(Hedblom 
and Kirkness, 1997) 
 
               
A B 
Figure 3 (A) A schematic presentation of the GABAA ion channel with the different modulator binding sites indicated. (B) Shows yet 
another schematic presentation showing the amino acids implicated in the binding of GABA and most of the classic benzodiazepines.       
                     
 
Pharmacological analysis of recombinant GABAA receptors has shown that the structural heterogeneity of the 
GABAA receptor may determine the functional and pharmacological properties of the receptor expressed at the cell 
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surface (Barnard et al., 1998; Sigel et al., 1990b). The α and β subunits participate in high affinity GABA/Muscimol 
∗ binding and play a vital role in receptor assembly (Taylor et al., 1999). 
The classical benzodiazepine∗ binding site has been localized, at the interface of the α and the γ subunit (Pritchett 
and Seeburg, 1990). Moreover α4 and α6 constitute a subfamily of receptors that are insensitive to classical, non-
selective benzodiazepine modulation. The γ is also essential to the modulatory action of benzodiazepines since the 
binding site for the benzodiazepines is between the αx and γ2 subunit  (Sigel et al., 1990a). 
 
The δ subunit is involved in neurosteroid modulation, agonist affinity and desensitization (Wohlfarth et al., 2002). 
The ρ-subunits is expressed primarily in the retina and confer a distinct pharmacology and are often termed 
GABAC receptors (Bormann, 2000). 
 
2.2. THE HYPOTHALAMUS 
 
In order to fully understand and appreciate the basic concepts of biological stress, it is necessary to introduce one 
of the major brain components, regulating the body’s endocrine, physical response to stress namely the 
hypothalamus. 
 
There is clinical as well as experimental evidence that the hypothalamus plays an important role in survival of both 
the individual as well as the species.  The common view is that the hypothalamus plays a pivotal role in integrating 
a wide range of endocrine autonomic and behavioural responses, which guarantee homeostasis and reproduction. 
Generally speaking, these responses are involved in regulating metabolism, and thereby providing an adequate 
nutrient and water intake, defending the animal from predators and other threats, and allowing the generation and 
care of offspring. The hypothalamus is involved in exploratory, digestive, thermoregulatory, aggressive-defensive, 
sexual and parental behaviours and these expressions are tied in a fundamental way to the circadian rhythm of sleep 
and wakefulness. 
There is abundant evidence that experimental manipulation of specific hypothalamic regions profoundly affects the 
expression of these behaviours. The complexity of the hypothalamus is immense and the attempts to understand 
its functions are based on three types of hypothesis which are in themselves not necessarily mutually exclusive. 
The first and earliest was laid down by Hughlings Jackson, Ramón y Cajal, and Sherrington and assumes that cell 
groups in the hypothalamus are nothing more than components of extensive central neural circuits which are 
particular important for the integration of somatomotor and viceromotor responses involved in homeostasis 
(Jackson and Schnieden, 1968). 
The second hypothesis was described as the stellar hypothesis and assumes that the hypothalamus contains an array 
of centres each of which plays a critical role in the inhibition or cessation of eating, drinking, and sexual behaviour 
(Stellar, 1954). The third and latest hypothesis is based on the conclusion that many behavioural effects of 
hypothalamic manipulations are the result of tampering with ascending or descending fibbers that pass through the 
hypothalamus (Morgan and Pfeil, 1979). The gap between structure and function is immense in the hypothalamus. 
The picture is further diffused by the fact that, cell groups and fibre tracts in this part of the brain is relatively 
poorly differentiated. 
 
The hypothalamus is the neuroendocrine control centre in the brain, from which autonomic and homeostatic 
regulation is achieved. The hypothalamus controls hormone secretion from the anterior and posterior pituitary. It 
also controls or modifies a number of homeostatic processes ranging from body temperature regulation, respiration 
and the ingestion of food and water.  
The integration of somatomotor, autonomic and endocrine responses which characterizes the expression of 
emotional behaviours, are often discussed in relation to the limbic system, and are also attributable in large part to 
the hypothalamus. The hypothalamus is able to exert such profound controls over these functions through a rich 
                                                     
∗ 5-(aminomethyl)-3-isoxazolol, potent GABAA agonist  
∗ Non subunit selective benzodiazepines, ex diazepam, midazolam 
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array of connections with the rest of the central nervous system. Notably are the brainstem reticular formation and 
autonomic zones, limbic forebrain (particularly amygdala) and cerebral cortex. 
2.2.1. DEVELOPMENT OF THE HYPOTHALAMUS  
 
The hypothalamus develops from the embryonic diencephalons, which is itself one division of the most anterior 
part of the three primary brain vesicles, the posencephalon (the other divisions being the telencephalon which 
becomes the cerebral hemisphere). It first appears as the lowest of the three swellings in the lateral wall of the third 
ventricle and it becomes separated from the other two, the epithalamus and the thalamus, by a longitudial groove 
called the hypothalamic sulcus. As the hypothalamus and thalamus develop in the lateral walls of the 
diencephalons, the thalamus unlike the hypothalamus develop in close association with the cortex. The central 
cavity between them is gradually transformed to the slit-like third ventricle. 
The roof of the third ventricle is formed by a single layer of ependyma covered by a capillary-rich mesenchyme. 
The local invagination of these capillaries together with the underlying ependyma forms the choroid plexus of the 
third ventricle. 
The hypophysis develops in close association with the hypothalamus, indeed the neurohypophysis develops as an 
evagination of the diencephalons called the infundibulum. By contrast the adenohypophysis (anterior lobe) has a 
non-neural origin developing as it does, from an ectodermal diverticulum of the primitive oral cavity called 
Rathke’s pouch. This diverticulum elongates dorsally to contact the down growing infundibulum with which it 
fuses, losing contract with the oral cavity. Cells from the adrenohypophysis extend along and around the pituitary 
stalk to form the pars tuberalis. Thus the neurohypophysis is in neural communication with the overlying 
hypothalamus. The adreno-hypophysis on the other hand has no direct contact with the hypothalamus but instead 
there is a rich vascular communication between the two, which is called the portal system. It is by this means that 
anterior pituitary secretion is controlled by the hypothalamus, that is, the two are in humoral contact (Hamilton and 
Mossman, 1982; Kandel et al., 2000). 
 
 
 
Figure 4 schematic drawing of the development of the hypothalamus  
 
 
2.2.2. ANATOMICAL BOUNDARIES 
 
From this developmental perspective it can be seen that the hypothalamus is situated at the base of the 
diencephalon beneath the thalamus, from which it is separated by the longitudinally running hypothalamic sulcus, 
which delimits the dorsal extent of the hypothalamus on each side of third ventricle. The rostral boundary of the 
hypothalamus is conventionally taken to be the lamina terminalis (which appears to run ventrally from the region of 
the anterior commissure to the base of the brain), while caudally the boundary is taken as an imaginary line, which 
extends between the caudal limits of the mammalian body below to the commissure above. These caudal and 
rostral boundaries are not well defined when examining the hypothalamus microscopically; it gives the expression 
that it merges with the surrounding parts of the CNS. Thus rostrally the hypothalamus continues through the 
preoptic area with the septal area and part of the anterior perforated substance. The anterior zone of the lateral 
hypothalamus merges laterally with the substantia innominata while more caudally it abuts the internal capsule 
(dorsolaterally) and globus pallidus (laterally and ventrally). Caudally, the hypothalamus is continuous with the 
central grey matter and tegmentum of the mesencephalon. The basal surface of the hypothalamus is defined by the 
optic chiasm rostrally and the mamillary bodies caudally. In between is a grey swelling called the turber cinereum 
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which, together with infundibular part of the adenohypophysis forms the hypophyseal stalk. This infundibular 
region at the base of the hypothalamus is also known as the median eminence. It is a very important site for 
vascular communication between hypothalamus and pituitary. The lateral eminence found at the lateral margin of 
the turber cinereum marks the site of the ventrally located lateral tuberal nuclei of the hypothalamus. 
 
 
Figure 5 illustrates the crucial parts involved in regulating the hypothalamic neuroendocrine response in humans.  (Psycheduation.org, 2005). 
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2.2.3. BLOOD SUPPLY 
 
The blood supply of the basal hypothalamus, infundibulum, hypophyseal stalk and pituitary gland is derived from 
the carotid arteries via the superior and inferior hypophyseal arteries. The more posterior part of the median 
eminence is supplied by separate vessels derived from the circle of willis, while the most ventral part of the 
hypphyseal stalk is supplied by the paired trabecular arteries. 
The majority of the blood supply of the adenohypophysis circulation is derived not from the hypophyseal arteries 
directly but indirectly through a capillary portal plexus. Thus the arteries supplying the median eminence, empty 
into a rich capillary network. Some of these capillaries form long loops, which extend upwards penetrating the 
palisade zone of the median eminence, almost the ventricular floor, while others are shorter and remain in a 
“mantle” plexus. The portal vessels run downwards on both sides of and behind the hypophyseal stalk to reach the 
adenohypophysis where the long portal vessels are joined by the short portal vessels, arising in the ventral-most 
hypophyseal stalk and derived in part from the inferior hypophyseal arteries. Some 90 % of adenohypophyseal 
blood supply arrives through these long portal vessels.  
There are relative few venous channels that run between the anterior pituitary and cavernous sinus, although this 
has been assumed to be the obvious route of venous drainage of the gland, ultimately leaving the skull via the 
jugular veins. Conversely numerous veins run between the neurohypophyseal and cavernous sinus. It has been 
suggested on the basis of such observations, that the major adrenohypophyseal venous drainage is through the 
short portal veins into the neurohypophyseal capillary plexus. Thus the flow of blood containing the 
adrenohypophyseal hormones might be regulated in part by those factors normally controlling the 
neuropypophyseal capillary plexus. Hence the direction of venous blood flow may vary during different 
physiological states, and may indeed reverse through the capillary plexus to reach the median eminence or through 
the arteries that supply large areas of the mediobasal hypothalamus. It has however not yet been established 
whether such retrograde flows of portal blood occurs under physiological circumstances nor if it does occur, what 
significance this may have for the feedback regulation of the hypothalamic hormone secretion or for the purposed 
central effects of the pituitary peptides. However there is a clear potential for dynamic, regulatory changes in the 
pituitary capillary bed. 
One additional important feature of the portal capillaries is that they share structural characteristics of peripheral 
not central capillaries. That is to say, the capillary endothelium is fenestrated and not marked by tight junctional 
complexes as in the case of cerebral capillaries. 
Thus it can be said, that the median eminence region of the hypothalamus lies outside the blood-brain barrier, the 
structural manifestations of which is provided by tight junctions between capillary endothelial cells. The 
characteristics of fenestrated cells are shared by the circumventricular organs, with which the median eminence is 
often grouped. (Krieger and Hughes, 1980; Palkovits, 1982). 
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Figure 6 Arteries and Veins of the human hypothalamus and pituitary (Psycheduation.org, 2005) 
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2.3. THE PARAVENTRICULAR NUCLEUS  
 
A crucial component of the stress response is the paraventrivular nucleus of the hypothalamus (PVN).  The 
following will in detail describe the histology as well as the anatomy of the PVN. 
 
The paraventricular nucleus (PVN) of the rat lies adjacent to the third ventricle in the anterior hypothalamus and is 
the most prominent of the group of anterior supra group of nuclei. 
 
 
Figure 7 Schematic presentation of the location of the PVN in the rat barin (Bains and Ferguson, 1995) 
 
 
 
 
Figure 8 Schematic presentation of the PVN anatomy (in humans) (Site de neuroanatomie et al., 2005) 
 
The rat PVN is comprised of a cell community of about 1500 cells (Kiss et al., 1983) Based on their morphology 
and efferent connections the majority of the paraventricular neurons seems to belong to three basic categories of 
cells. Along with the supraoptic nucleus (SON) the PVN contains the majority of magnocellular neurosecretory 
neurons in the hypothalamus, these relatively large cells secrete vasopressin the antidiuretic hormone and oxytocin, 
a hormone involved in milk ejection, parturition as well as in ejaculation in man, the axons of these cells project to 
the posterior lobe of the pituitary gland, where they secrete their hormonal content directly in to systemic 
circulation. 
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Secondly the PVN contains a large population of parvocellular neurosecretory cells. These neurons form part of 
the hypothalamic hypophysiotropic systems that control the release of pituitary hormones. The axons of the 
paraventricular hypophysiothropic cells project to the external zone of the median eminence and release their 
neurohormonal content into the portal capillary system that “irrigates” the portal anterior lobe cells. These cells 
provide CRH (corticotrophin releasing hormone) and regulate pituitary-adrenocortical activity. 
Other hyphysiotrophic neurons in the PVN produce thyroid releasing hormone and regulate the release of thyroid 
stimulating hormone thus the PVN participate in the regulation of the body’s temperature metabolism (Kiss, 1988). 
Finally, paraventricular parvocellular neurons may provide VIP, the putative prolactine releasing hormone releasing 
factor to the median eminence. Many other peptides have been localized in the parvocellular neurons including 
cholecystokinin (CCK), substance P, neurotensin, atriopeptin), Galaning, SOM enkephami, growth hormone 
releasing factor, angiotensin II, Oxytocin and VP (Kiss et al., 1983; Kiss, 1988). 
The third major population of neurons, the “autonomic cells,” has been shown to send projections to the brain 
stem and spinal cord. Descending fibres of these neurons travel to the dorsal motor nucleus of the vagal nerve and 
the intermediolateral column of the spinal cord where they innervate parasympathetic and sympathetic 
preganglionic cells respectively. In addition, these neurons innervate a number of other regions associated with the 
autonomic nervous system including the nucleus of the solitary tract, the Edinger-Westphal nucleus, the 
parabrachial nucleus, the locus coeruleus and the pedunculopontine nucleus. The periaqueductal grey, the sensory 
nucleus of the trigeminal nerve and the substantial gelatinosa of the dorsal horn of the spinal cord is another target 
for descending PVN projections. The neurons that give rise to these projections are small to medium size cells in 
the dorsal and caudal portions of the nucleus. These cells contribute about 30% of all axons descending from the 
hypothalamus. It is worth recalling that a significant number of the “autonomic” cells were shown to contain 
oxytocin or vasopressin. Through these descending projections, the PVN may influence cardiovascular functions, 
analgesia, control of food and water intake, gastrointestinal functions, as well as melatonin synthesis in the pineal 
gland. The existence of neurons involved in the three homeostatic systems (the magnocellular neurosecretory, the 
parvocellular neurosecretory and the “autonomic” cells) in one nucleus is unique in the hypothalamus. On the basis 
of this anatomy, it has been proposed that the PVN has a pivotal role in integrating autonomic and neuroendocrine 
functions.(Swanson and Kuypers, 1980). 
 
 
Figure 9 “Schematic frontal view of the hypothalamic paraventricular nucleus of at the central level. Individual sub nuclei are depicted using 
the nomenclature of (Swanson and Kuypers, 1980)” (Larsen et al., 1994) where mp is the medial parvocellular subdivision and pm being the 
posterior magnocellular cellular part, pm is the posterior magnocellular part, and dp is the dorsal parvocellular part, lp is the lateral 
parvocellular part.    
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Figure 10 “The three major efferent systems are shown together with the known neurotransmitter (neuropeptide) content of the different 
pathways. For reference see the present review. The magnocellular population that projects to the posterior lobe contains vasopressin, 
oxytocin and several coexisting peptides. The parvocellular neurosecretory division (2) projecting to the median eminence mainly contains 
neuropeptides that are involved in hypophyseotropic functions. The descending projections to the brainstem are mostly oxytocinergic. 
Abbreviations: AIIangiotensin II; CCK-cholecystokinin; CRF-coticotropin releasing factor; DYN-dynorphins; ENK-enkephalins; GAL-
galanin; OX-oxytocin; PHI-VIP related peptide; SOM-somatostatin; SP-substance P; TRH-thyrotropin releasing hormone; vasopressin; 
MFB-median forebrain bundle; PVN-Pam ventricular nucleus; 3V-third ventricle; d-dorsal subdivision; p-medial parvocellular subdivision, 
m-magnocellular subdivision.”  (Kiss, 1988) 
2.3.1. ANATOMY OF THE PVN 
 
The paraventricular nucleus lies adjacent to the third ventricle in the anterior hypothalamus. The most striking 
architectural characteristic of the nucleus is its division into various sub nuclei. Magnocellular neurosecretory, 
parvocellular neurosecretory and “autonomic” cells tend to segregate and are localized within certain anatomical 
boundaries. The most obvious demarcation, though not complete, is seen between the “compact” magnocellular 
and the parvocellular divisions. In the rat, there are approximately 6000 magnocellular and 11000 parvocellular 
neurons (Kiss et al., 1983; Kiss, 1988). The magnocellular division is constituted of magnocellular neurosecretory 
cells, and can be further subdivided into at least two, topographically segregated, cytoarchitectonic subdivisions.  
The parvocellular part appears to be formed by at least 4 parvocellular neurosecretory and 2 “autonomic” 
subdivisions. It has become clear that cytoarchitectonic subdivisions comprise functionally distinct subgroups of 
neurons. For example, separate populations of magnocellular neurons, distributed within the same magnocellular 
subdivision, produce oxytocin or vasopressin. Similarly, discrete populations of parvocellular neurosecretory cells 
appear to contain TRH, CRF, or VIP. It seems that neurons having different neurotransmitters are not randomly 
mixed within an anatomical subdivision. Cells which have been found to synthesize the same substance have a 
tendency to reside adjacent to each other. Anatomical subdivisions of the PVN can be further subdivided into 
neurochemically specialized and topographically segregated “subunits” of neurons.  
It is clear that paraventricular afferents preferentially innervate certain subdivisions and seem to exhibit 
homogenous densities over subpopulations of cells. For example, the noradrenergic innervations from the A 1 cell 
group in the brain stem is mainly directed at vasopressin-producing magnocellular neurons as opposed to those 
that produce oxytocin. Similarly, ACTH-immunoreactive input appears to innervate periventricular and caudal 
paffocellular regions while this input is only sparsely distributed in regions where CRF containing parvocellular 
cells are distributed. In contrast, epinephrine-containing fibers seem specifically to terminate on neurons containing 
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CRF and on neurons sending projections to the brain stem. This, of course, does not necessarily mean that CRF 
neurons are the only target of epinephrine containing axons. In fact scattered epinephrine fibers and varicosities 
can be found all over the PVN. However, it is possible to determine a distribution pattern of these axons, which 
seems to exhibit high, even densities over certain subgroups of neurons. It is important to emphasize that subsets 
of neurons specified by their neuromediator content are not strictly demarcated anatomical formations (Everitt and 
Hokfelt, 1990; Kiss, 1988). 
 
 
2.3.2. THE SUBPARAVENTRICULAR AREA 
 
The immediate area surrounding the PVN is richly innervated by a number of limbic structures implicated in the 
HPA axis regulation, including the ventral subiculum, prefrontal cortex, lateral septum, medial amygdala, PVN and 
suprachiasmatic nucleus (SCN) (Canteras et al., 1995; Risold et al., 1997; Herman et al., 2002). Anterograde tracing 
studies indicate that all of these regions innervate the SubPVN area while almost completely avoiding the medial 
parvocellular are of the PVN (Herman et al., 2002). The medial parvocellular PVN neurons are very limited 
dendritic trees largely contained within the PVN itself  (Rho and Swanson, 1989) thus terminal boutons of limbic 
afferents to the SubPVN and the region immediately adjacent to the lateral and dorsal limits of the PVN proper do 
not appear to contact the parvocellular neurons, but rather act through local interneurons. A substantial proportion 
of local neurons contacted by descending limbic projections are likely to be GABAergic in phenotype (Bowers et 
al., 1998). Previous studies indicate that the vast majority of PVN-projecting neurons in the hypothalamus and the 
bed nucleus of the stria terminalis (BNST) are glutamic acid decarboxylase (GAD) m-RNA -positive (Bowers et al., 
1998)  The immediate surroundings of the PVN is particularly rich in GABAergic neurons that project into the 
PVN. These cell populations are stress-responsive, showing upregulation of the GABA synthesizing enzyme GAD 
(Bowers et al., 1998) as well as c-FOS induction following stress exposure (Cullinan et al., 1996)). As such, these 
neurons are putative targets for descending information relevant to the HPA axis function. 
 
The PVN-projecting cell populations co-express glutamate receptors and GAD mRNA, which indicate that 
SubPVN GABAergic neurons are likely to integrate glutamatergic neurotransmission.  
Similar to glutamate receptors, studies have revealed that GABA receptors are expressed in the parvocellular PVN 
and adjacent territories (Cullinan, 2000). GABAA receptor mRNAs specific for the α1-2 β1-3 and γ1-2 subunits have 
been found to be expressed within hypophysiotropic CRH neurons in the PVN, as well as within the SubPVN 
zone (Kiss, 1988). These receptors are also variably expressed within additional intrahypothalamic regions that send 
local projections to the parvocellular PVN (medial preoptic area, dorsomedial hypothalamic nucleus), indicating 
that these areas serve as GABA-to-GABA relays capable of disinhibiting CRH cells. 
Exposure to chronic (nonhabituating) stress results in a down-regulation of transcripts encoding the β1 and β2 
subunits of the receptor in the parvocellular PVN without changes in the β3 subunit, suggesting the possibility that 
GABAA receptors might be decreased in CRH-containing cells, or alternatively, that changes in subunit 
composition may occur that alter GABAA receptor efficacy at this key regulatory site (Herman et al., 2002). 
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Figure 11 ”Three-dimensional rendering of the presynaptic GABAergic sites depicted in three planes”  (Herman et al., 2002) 
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2.4. BIOLOGICAL STRESS 
 
Stress is a condition originally defined by Hans Selye, to describe the pathophysiological state associated with 
specific physiological changes that could be induced by diverse physical or physiological stimuli (selye, 1936). 
The research of Hans Selye in the 1940s lead to further characterisation of the “general adaptation syndrome” and 
the proposal that the pituitary was critical for the control of endocrine secretion, including those of the adrenal 
glands. He proposed that the adrenocorticotropic hormone (ACTH) released from the pituitary lobe, was 
associated with increased production of glucocorticoids from the adrenal glands that excerted profound and 
widespread effect on the metabolism and lymphoid organ activity. 
In addition to activation of the pituitary-adrenocortical system, endocrine responses to stress include activation of 
the symphathic nerves that innervates the adrenal directly. In response to stress the symphatic activation enhances 
secretion of the adrenal catecholamines, principally the hormone adrenalin, which is important in the regulation of 
the autonomic response to stress (Able, 2005). 
 
The endocrine system encompasses the pituitary gland, the peripheral endocrine organs and the hormones the two 
produce. The pituitary gland or the hypophysis is responsible for the production of a range of hormones that has 
influence over a wide array of bodily functions. 
The pituitary is subjected to afferent control via the actions of specific hypothamlamic releasing or inhibiting 
factors that act on the pituitary cells in order to regulate synthesis and release of pituitary hormones. 
Stress influences the neuroendocrine regulation of a number of pituitary hormones including ACTH, prolactin, 
growth hormone, luteinising hormone (LH), tyroprotrophin, vasopressin and oxytocin. 
Upon release into the hypophysial blood supply the hypothalamic-releasing factors; Corticotropin-releasing 
hormone (CRH) and the nonapeptide arginine vasopressin (AVP) are transported to the adrenohypophysis where 
they activate pituitary cortitrophs which in turn, synthesis and release ACTH in to the general circulation (Able, 
2005). 
In the blood ACTH passes to the adrenal gland where it binds to receptors on the cells of the zona fasciculata of 
the adrenal cortex to promote the conversion of cholesterol esters into to free cholesterol, and stimulate the 
steriogenic pathways. This causes a rapid enzymatic conversion of precursor cholesterol into steroid intermediates 
ultimately resulting in the formation of the end product of the steroid pathway, the glucocortiticoids, cortisol in 
man and corticosterone in rodents who lack the enzyme (C-17 hydroxylase) (Cooper and Bloom, 2003).  
In conditions that is associated with chronic ACTH secretion cortisol release may increase several times resulting in 
secretion rates of up to 200-250 mg/day. In the rat corticosterone is the principle HPA end product, and small 
amounts of this steroid are also secreted in humans (1-4 mg/day). The amount of ACTH present in the plasma, is 
the major factor regulating the glucocorticoid release. However, additional hormones from the adrenal medulla are 
involved but to a much lesser extent (Bornstein et al., 2000). 
 
The principle role of the glucocorticoids is to produce homeostatic adaptation to stress and this is achieved 
through catabolic actions that mobilise energy resources, increasing blood pressure, at the same time suppressing 
hunger and sexual behaviour. (Able, 2005) 
 
A central component of the HPA axis is the parvocellular part of the paraventricular nucleus (PVN). It is here that 
CRH and AVP is synthesized in the tuberoinfundibular parvocellular cells. CRH and AVP in turn evoke the release 
of ACTH via their synergistic actions on the pituitary corticotrophs. 
The axon terminals of the parvocellular neurons terminate in the external zone of the median eminence adjacent to 
the capillaries of the hyperphysial portal blood supply, where they secrete their content into the portal blood 
circulation. Parvocellular AVP, in contrast to magnocellular AVP is involved in regulation of pituitary ACTH 
release and does not contribute to osmotic balance regulation. CRH is the primary source of ACTH secretagogue 
while AVP colocalises with CRH in approximate 50 % of the CRH containing neurons of resting animals and 
humans (Able, 2005; Whitnall, 1993). It has been shown in vitro by (Gillies et al., 1982) and in vivo by (Rivier and 
Vale, 1983) that AVP potentiates the effect of CRH on the ACTH secretion. AVP alone has little or no effect on 
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ACTH secretagogue activity. In addition to inducing ACTH release CRH induces transcription of pro-
opiomelanocortin (POMC) mRNA, which encodes the ACTH precursor protein (Lightman and Young, III, 1988). 
 
During stimuli that activate the HPA axis, synthesis and secretion of CRH and AVP is increased, this in turn has 
profound effect on the amount of ACTH and glucosteroid secretion. Thus expression of CRH mRNA and AVP 
mRNA in the PVN is increased and POMC mRNA expression in the adrenohypophysis in response to stress. In 
addition to AVP several neuropeptides are co-localised with the parvocellular CRH neurons of the PVN including 
enkephalin, neurotensin, cholecytokinin, vasoactive intestinal peptide and galanin. CRH containing CRH neurons 
has also been reported to be co-localised with neurons expressing GAD (Meister et al., 1988). The co-localization 
of CRH and GAD provides a way of subtle regulation of ACTH release. 
 
 
Figure 12 ”The two major components of the pituitary gland” (Rosenzwig et al., 1996) 
 
2.4.1. THE HPA AXIS AND THE CIRCADIAN RHYTHMS 
 
Glucocorticoid secretion varies through out the day in a pulsating fashion, the same principle applies to ACTH, 
and thus circulating levels of ACTH mirrors the levels of glucocorticoids. The maximum levels of glucocorticoids 
peak approximately 15-20 minuets after a pulse of ACTH in normal human subjects, a major peak of ACTH 
occurs in the early hours of the morning. Following this major pulse of ACTH and glucocorticoids, secretion is 
stimulated by further pulses through the day. 
The subparaventricluar zone (SubPVN) receives massive projection of vasopressin-containing neurons from the 
suprachiasmatic nucleus (SCN). The dorsal and lateral compartments of the parvocellular part of the PVN also 
receive projection from the SCN (Vrang et al., 1995). 
The SCN is involved in control of the body’s circadian rhythms; however the SCN may also be involved in the 
actual stress response, it has been shown that evening activation of the SCN, results in a surge of ACTH and in 
turn glucocorticoids (Cascio et al., 1987). 
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2.4.2. NEGATIVE FEEDBACK REGULATION OF THE HPA AXIS 
 
In order to prevent excessive and potentially dangerous overproduction of glucocorticoids, the HPA axis functions 
as a closed-looped system. The production of glucocorticoids is tightly regulated via a negative-feedback system. 
Regulatory feedback occurs at several sites and involve both rapid feedback and delayed feedback in humans and 
rats (Keller-Wood and Dallman, 1984; Able, 2005). Rapid feedback occurs immediately following a surge in 
glucocorticoids and will last between 5 to 15 min whereas delayed feedback is initiated 1-2 hours later and usually 
persists up to 5 hours and is dependent on the concentration of glucocorticoids. Delayed feedback can persist up 
to 24 hours, this suggests that delayed feedback is a consequence of genomic action of the glucocorticoids whereas 
the rapid feedback is exerted primarily via the direct inhibitory action of the glucocorticoids on the synthesis and 
release of ACTH at the hypothalamic level by decreasing the level of mRNA expression of CRH and AVP (Able, 
2005). 
 
The actions of the glucocorticoids are mediated through two distinct types of receptor complexes, the 
mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR). 
The GR and MR receptors are located inside the cytoplasm, here they bind steroids that diffuse across the plasma 
membrane, once bound, the receptor ligand-complex translocates to the nucleus and interacts with the palindromic 
hormone response element on the DNA molecule. Thus activated steroid receptors function as transcriptions 
factors, that influence transcription of target genes, which ultimately leads to changes in protein synthesis (Able, 
2005). 
The MR receptor is primarily distributed in the hippocampus, and in sensory and motor nuclei outside the 
hypothalamus (Reul et al., 2000). The GR receptor is however more widely distributed in the hypothalamus, PVN 
and brainstem, amygdala and hippocampus in addition to the pituitary gland. Especially the hippocampus is a very 
important structure in the negative-feedback regulation of the neuroendocrine stress response both MR and GR 
are present in this brain structure. Lesions of the hippocampus-PVN (the BNST) connections result in a higher 
basal level of glucocorticoids and in abnormal feedback regulation (Herman et al., 1992). 
 
 
2.5. C-FOS AS A MARKER OF ACTIVITY IN NEUROENDOCRINE SYSTEMS. 
 
 
Large parts of the present study, is based on immunocytochemical studies using FOS, the protein product of the 
immediate early gene C-FOS, as a marker of transient neuro-activity. The following section will try to justify using 
FOS as a biomarker of neuroendocrine activity 
 
In the late 1980s it was discovered that neurons transiently expressed C-FOS when stimulated either electrically, 
with growth factors or with neurotransmitters. The protein gene product FOS is localized in the nucleus and can 
easily be detected using immunocytochemistry.      
 
The immediate-early gene, c-FOS, is rapidly expressed in several brain sites in response to various physiological and 
pharmacological stimuli, including growth factors, neurotransmitters, electroconvulsive shock, osmotic challenge, 
and stress (D'Costa et al., 1991; Curran and Morgan, 1985; Ceccatelli et al., 1989; Arnold et al., 1992). 
The c-FOS gene encodes the nuclear regulatory factor, FOS, which forms heterodimeric complexes with protein 
products of the jun proto-oncogene family (c-jun, jun-B, jun-D)(see figure 11); the resultant heterodimers regulate 
gene transcription upon binding to genomic AP-1 sites (Curran and Franza, Jr., 1988; Cohen et al., 1989). FOS and 
other regulatory proteins function as signalling molecules linking intracellular second messenger systems to target 
genes. FOS is not normally expressed constitutively by most central neurons, but only expressed transiently 
following stimulation (Curran and Morgan, 1985).  
 
Thus, demonstrability of either C-FOS m-RNA, or FOS protein is an indicator of a transcriptional-activated cell 
populations within the central nervous system (Sagar et al., 1988).  
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The hypothalamus functions to integrate neuroendocrine, autonomic, and behavioral responses to stress. Studies 
have sought to characterize the distribution and mean numbers of neurons in the hypothalamus and the adjacent 
preoptic area, that are activated via the FOS stimulus-transcription cascade in response to stress. There is 
consistent evidence that parvocellular neurons in PVN, express FOS immunoreactivity in response to intense stress 
stimuli, e.g., immobilization or foot shock (Arnold et al., 1992; Smith et al., 1992; Kononen et al., 1992). 
 
C-FOS expression and neuron-firing is frequently linked, however depolarization and expression of c-FOS might 
be dissociated. When using FOS to study neuronal systems it is essential to keep in mind, that it is the changes in 
signal transduction pathways which induce c-FOS expression, not depolarization in itself. There are 3 major 
regulatory pathways for induction of FOS; for a schematic presentation (see figure 13)  
 
 
Figure 13 “Illustration of the principal signal transduction pathway that evoke FOS in the neurons” (Hoffman and Lyo, 2002). 
 
One of the pathways involved in c-FOS induction results in either increased intracellular calcium or increased 
levels of cyclic AMP acting through a calcium response/cyclic AMP responsive element (CaRE/CRE) on the c-
FOS promoter (Sheng et al., 1990; Sassone-Corsi et al., 1988).  
A second transduction cascade operates via serum response factors (SRFs) which activate a DNA serum response 
element (SRE) independent of cyclic AMP (Gilman, 1988).  
A wide number of transmitter receptors, when occupied, increase intracellular cyclic AMP levels or activate voltage 
sensitive calcium channels leading to the phosphorylation of CREB and c-FOS induction (Thompson et al., 1995). 
These are frequently engaged by stimuli that evoke increased firing in the target neurone. This feature forms the 
basis of using FOS as a marker for stimulated neurone activity. However, there can be changes in second 
messenger systems without accompanying depolarization just as there can be depolarization without FOS 
expression. 
 
2.6. RETROGRADE NEUROTRACING USING CHOLERA TOXIN SUBUNIT B 
Part of this study utilises Cholera toxin subunit B as a retrograde tracer, the following section will briefly give some 
essential background on the tracer. 
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Cholera toxin is an oligomeric protein of MW 84,000 daltons and consists of a single A subunit surrounded by five 
B subunits (Gill, 1976; Finkelstein et al., 1974). The A subunit is a potent activator of adenylate cyclase and is the 
pathogenic agent responsible for the symptoms of cholera. The B subunit (choleragenoid) is responsible for the 
binding of the holotoxin to GM1 ganglioside receptors on mammalian cell surfaces (Holmgren and Lonnroth, 1975) 
and facilitates entrance of the A subunit into the cell. The A subunit bears the ADP-ribosyl-transferase activity, 
which deregulates the Gs protein causing activation of adenylate cyclase. Due to the ubiquitous occurrence of the 
GM1 ganglioside receptor on eukaryotic cell membranes, cholera toxin activates adenylate cyclase in a wide variety 
of systems. 
The cholera toxin B subunit can be used for tract tracing in neurological research, taking advantage of GM1 
ganglioside binding and retrograde transport, and since ChB is a protein it can easily be detected using 
immunocytochemistry.  
 
Figure 14 shows the principle of retrograde tracing where the tracer is transported towards the cell body.  
2.7.  BENZODIAZEPINES 
 
Benzodiazepines are probably the most widely taken family of psychotropic drugs in the history of modern 
medicine. Therefore it would be out of the scope for this project to describe every detail from synthesis to 
pharmacology of the benzodiazepines. 
 
In the 1950s meprobamate (Miltown®), a propanediol carbamate, was available for use as a “tranquilizer”, 
meprobamate was more safe than the early barbiturates, but still had many problems. 
The goal of the pharmaceutical industry was to produce a drug that selectively relieved anxiety without causing 
overt intoxication or general sedation. 
The separation of the ability to dull certain mental faculties from general sedation had already been demonstrated, 
with the phenothiazines, notably chlorpromazine (Thorazine®). At the time, no one thought of these drugs as 
"antipsychotic agents" – there probably would have been a fair amount of chortling, were someone to use a term 
with such sweeping and entirely baseless implications. Instead, these agents were called neuroleptic (lobotomizing) 
drugs, or simply major tranquilizers. 
 
In the mid 1950s the Hoffman-LaRoche company with chemist Leo E. Sternbach and pharmacologists Lowell 
Randall began a systematic search for minor tranquilizers. Chlordiazepoxide (RO 5-0690) was the result of a 
mistaken synthesis on the part of one of Sternbach's bench chemists of the last of a series of analogs of a certain 
dye compound (which they thought were heptodiazines, but which turned out to be quinazolone-3-oxides) they 
had been making.  Randall's pharmacologists wondered why RO 5-0690 alone showed all of these behavioural 
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properties (most notably, "taming" at vastly sub-ataxic doses), when the prior 39 analogs were all inactive. The 
answer turned out to be that it wasn't an analog after all – it was a brand new compound, the first of the 
benzodiazepines, which was initially called methaminodiazepoxide and then chlordiazepoxide (CDZ), which 
remains its USAN name1. Chlordiazepoxide goes by the trade name Librium®. 
 
Benzodiazepines act selectively on the GABAA receptor, which as stated earlier mediate fast inhibitory synaptic 
transmission in the CNS. Benzodiazepines enhance the response of GABA, by facilitating the opening of GABA-
activated chloride channels. They bind specifically between the α and γ subunit of the GABAA receptor which is 
distinct from the GABA binding site and here benzodiazepines act by allosterically increasing the affinity of GABA 
for the receptor. (Rang et al., 2004)  
2.7.1. BASIC CHEMISTRY 
 
Pharmacology is a combination of physiology and organic chemistry, 1,4-Benzodiazepin is the basic structure of a 
benzodiazepine from a chemical perspective. 
 
 
 
Figure 15 1,4 Benzodiazepine 
 
However from a pharmacological perspective, there are several additional features required before any drug activity 
is seen. 
 
 
Figure 16 1,4 Benzodiazepin-2-one 
 
 
Almost all active benzodiazepines except those possessing a fused heterocyclic ring or a thionyl group have a 
carbonyl group at position 2. Two additional features are required before we have a pharmacological active 
benzodiazepine skeleton. The first of these is another benzene ring (phenyl group), the second is an electron-
withdrawing group, and there must be an electronegative group at position 7, for example chloride, fluoride, and 
bromide. 
 
                                                     
1 United States Adopted Names Designation for nonproprietary names (for drugs) adopted by the USAN Council 
in cooperation with the manufacturers concerned; the designation USAN is applicable only to nonproprietary 
names coined since June 1961 
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Elektron attracting  
group 
Figure 17 N-methyl-7-chloro-5-phenyl-1,4-Benzodiazepin-2-one (Diazepam) 
2.7.2. ZOLPIDEM  
 
 
Figure 18 Shows the chemical structure of Zolpidem (N,N,6-trimethyl-2-(4-methylphenyl)imides[1,2-a]pyridine-3-acetamide hemitartrate) 
  
 
 
Zolpidem is an imidazopyridine which differs in structure from the benzodiazepines and zopiclone. It is a 
strong sedative with only minor anxiolytic, myorelaxant and anticonvulsant properties, and has been 
shown to be effective in inducing and maintaining sleep in adult patients suffering from insomnia (Salva 
and Costa, 1995).  
Zolpidem, like other benzodiazepines, displays a high affinity to GABAA receptors, containing the α1 
subunit and intermediate affinity to α2- and α3-GABAA receptors and fails to bind to α5-GABAA 
receptors (Crestani et al., 2000; McKernan et al., 2000j; Salva and Costa, 1995; Salva and Costa, 1995c).. 
Zolpidem potentiates the effect of  GABA at the GABAA receptor α1 complex with up to 400 % using 
whole patch clamp on Purkinje and striatal neurons (Itier et al., 1996; Crestani et al., 2000). 
2.7.3. DIAZEPAM 
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Figure 19 shows the chemical structure of Diazepam (N-methyl-7-chloro-5-phenyl-1,4-Benzodiazepin-2-one)  
 
 
Diazepam (Valium) was introduced by a Swiss drug company called Roche Labs in 1963, where it quickly 
became one of  “mother's little helpers” for millions of  housewives throughout the '60s and beyond. 
Throughout the history of  prescription medication, Valium was the first billion-dollar medicine and one 
of  the first brand-name drugs. Valium launched the era of  blockbuster medicines. More prescriptions 
were written for Valium than for any other drug between 1969 and 1982. However, today the drug is not 
taken with the same frequency due to adverse effects such as amnesia, and the high risk of  dependency. 
 Diazepam is a non selective GABAA  agonist (Benson et al., 1998), Diazepam binds at the 
benzodiazepine binding pocket between the γ2 and respective αx subunit, with equal affinity for the 
GABAA α1, α2, α3 and α5 , not α4/α6  (Scott-Stevens et al., 2005). Studies in genetically modified mice 
(McKernan et al., 2000) and transfected human embryonic kidney cells (HEK cells) using patch clamp 
(Benson et al., 1998) have shown that a crucial element for diazepam binding is a His residue located at 
position 101, when substituted with Arg there is a markedly reduced binding of  diazepam to the GABAA 
receptor (Benson et al., 1998).  
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2.7.4. ZOPICLONE  
 
 
Figure 20 Shows the Chemical structure of Zopiclone (4-methyl-1-piperazinecarboxylic acid 6-(5-chloro-2-pyridinyl)-6,7-dihydro-7-oxo-5H-
pyrrolo[3,4b]-pyrazin-5-yl ester) 
 
Zopiclone, is a cyclopyrrolone derivative, the drug is used as a short-acting hypnotic. Although 
structurally unrelated, it has a pharmacologic profile similar to that of  benzodiazepines. Following oral 
administration, the drug is rapidly absorbed, with a bioavailability of  approximately 80% and an 
elimination half-life that ranges from 3.5 to 6.5 hours. Zopiclone is well tolerated and effective and is a 
suitable alternative to benzodiazepines for short-term treatment of  insomnia. Rebound insomnia is 
substantially less frequent with zopiclone compared with hypnotic benzodiazepines.  
Several studies have shown that although zopiclone has high affinity for the GABAA receptor it does not 
discriminate between the different GABAA α subunit compositions (Sanger, 2004; Goa and Heel, 1986). 
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2.7.5. L-838,417 
 
 
Figure 21 Shows the chemical structure of L-838,417 (7-tert-Butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-[1,2,4]triazol-3-ylmethoxy)-
[1,2,4]triazolo[4,3-b]pyridazine). 
 
The anxiolytic compound L-838,417 is a selective GABA agonist with nanomolar affinity for the 
benzodiazepine binding site on the GABAA receptor.  
L-838,417 has high affinity for receptors with, α2β3γ2, α3β3γ2 and α5β3γ2 markedly lower for receptors 
containing α1β3γ2, α4β3γ2 and α6β3γ2. (McKernan et al., 2000). 
The efficacy of  L-838,417 at the BZ site has been measured by whole-cell patch-clamp recording from 
Ltk- cells expressing the same GABAA receptor subtypes. The degree of  potentiation of  a submaximal 
GABA concentration (EC20) has demonstrated that L-838,417 has no efficacy at the α1 subtype (it is a 
weak antagonist) and is a partial agonist with equal efficacy at the α2, α3 and α5 subtypes (McKernan et 
al., 2000). 
In contrast to diazepam L-838,417 does not impair the motor performance of  wild type mice on the 
rotarod at doses up to 30 mg/kg. With this in mind, it can be said that L-838,417 is a true anxiogenic 
with very little of  the normal negative side effect of  the classical benzodiazepins. 
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3. METHODS AND MATERIALS. 
 
3.1. COMPOUNDS  
 
Zolpidem and zopiclone were purchased from Tocris Ltd. (Bristol, UK). Diazepam was purchased from Sigma-
Aldrich (St. Louis, USA). L-838,417 was synthesised by the Department of Medicinal Chemistry, NeuroSearch 
A/S. All compounds were dissolved in 5% Chremophor and administered intraperitoneally (IP). 
 
3.2. ANIMALS  
 
Adult male NMRI mice weighing 30-35 grams were purchased from Harlan Inc (Hamburg, Germany). The animals 
were received at the animal facility at Neurosearch, and housed 5 per cage under 12:12 light: dark cycle, humidity in 
a temperature controlled room for at least 7 days before the experiment. Food and water were available ad libitum. 
All procedures were conducted in accordance with the Danish National Guide for Care and Use of Laboratory 
animals (justits ministeriet, 2003). 
 
Adult male Wistar Rats 180-220 grams were purchased from Harlan Inc (Hamburg, Germany). The animals were 
received at the animal facility at Neurosearch, and housed 2-3 per cage under 12:12 light: dark cycle, humidity in a 
temperature controlled room for at least 7 days before the experiment. Food and water were available ad libitum. 
All procedures were conducted in accordance with the Danish National Guide for Care and Use of Laboratory 
animals (justits ministeriet, 2003). 
 
3.3. SINGLE DOSING OF DRUGS  
 
In order to analyse the dose-dependent effect of all benzodiazepine ligands on circulating corticosterone, mice (n = 
5) were administered the drugs at doses 0,025, 0.1, 0.5, 2.5, 12.5, and 25 mg/kg ip. The mice were returned to their 
home cages and sacrificed by decapitation 60 min after drug administration. Trunk blood was collected in 
centrifuge tubes containing 2 mg EDTA and stored at -20°C. 
Another experiment was carried out in order to determine the temporal profile of HPA axis activation by 
zolpidem, these mice  were treated with 12,5 mg/kg zolpidem and the animals were sacrificed and trunk blood was 
taken at various time points after drug administration (t = 5, 10, 15, 30, 60, and 120 minutes). The blood was 
collected in EDTA containing tubes, kept at 4°C and plasma was isolated by centrifugation and stored at - 20°C 
until processed. 
 
3.4. COMBINATION OF DRUGS 
 
In order to investigate the relationship between activation of  α1 and non– α1 containing GABAA 
receptors, combinations of  L-838,417 (12.5 mg/kg i.p.) or vehicle was given 15 min before a single dose 
of  zolpidem i.p at increasing concentrations (0.5, 2.5, and 12.5 mg/kg). L-838,417 acts at the 
benzodiazepine binding site and is a functionally selective agonist at α2, α3, and α5 subtypes. In addition, 
L-838,417 is an antagonist on the α1 site; it might be that any inhibition result from its antagonistic 
properties. Therefore, combination of  the non-selective benzodiazepine ligand diazepam and zopiclone 
was tested together with zolpidem. In this case mice were treated with vehicle, diazepam (0.5 mg/kg i.p.) 
or zopiclone (0.5 mg/kg i.p.) 15 min before administering the mice with 0.5 mg/kg zolpidem or 2.5 
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mg/kg. The animals were sacrificed 60 min after zolpidem and trunk blood was taken for corticosterone 
measurements. All single and combined dosing experiments were carried out twice. 
 
3.5. RADIOIMMUNOASSAY  
 
All plasma Corticosterone measurements were carried out using a commercially available solid face 
radioimmunoassay [125I] kit from DCP diagnostics. ACTH measurements were carried out using a [125I] 
kit from Amersham. 
The general principle of  the two kits is the same and is briefly described below:    
I125-labelled rat corticosterone or ACTH competes for a fixed time with corticosterone/ACTH in the 
plasma sample for antibody sites. The antibody is immobilized to the wall of  a polypropylene tube, so 
decanting the supernatant is sufficient to terminate the competition and to isolate the antibody-bound 
fraction of  the radiolabelled corticosterone. Counting the tubes in a gamma counter, then yields a 
number which converts by way of  a calibration curve to a measurement of  the corticosterone content of  
the sample (Gwosdow-Cohen et al., 1982; Gomez-Sanchez et al., 1975) 
3.6. FOS STUDIES  
 
Adult male NMRI mice weighing 30-35 grams purchased from Harlan Inc (Hamburg, Germany) were 
used for the C-FOS immunohistochemistry studies. The animals were administered intraperitoneally (i.p) 
with 0,1, 0,5, 2,5 and 12,5 mg/kg diazepam, zopiclone, zolpidem, L-838,417 or vehicle (5% chremophor) 
at 4 hours after the onset of  the light phase and returned to their home cage. Sixty minutes after the 
injections the animals were deeply anesthetised with mebumal and perfused transcardially with 0.9% 
saline followed by 4% paraformaldehyde in 0.1M phosphate buffer (pH 7.4) for 5 min. The brains were 
post-fixed over night in 4% paraformaldehyde and subsequently submerged in 20% sucrose in 0.01M 
buffered saline (PBS) at 4ºC overnight. 40 μm serial coronal sections were cut through the hypothalamus 
on a freezing sledge microtome in series of  four and stored in a solution containing ethylene glycol 
glycerol in 30% sucrose at -20ºC until further processing. Prior to the immunocytochemical steps, the 
sections were rinsed for 3 x 10 min in 0.01M PBS, in 1% H2O2–PBS for 10 minutes, and in PBS with 
0.3% Triton X-100, 5% swine-serum, and 1% bovine serum albumin (BSA) for 30 min. Then the 
sections were incubated at 4°C for 24 hours in an antiserum against FOS (code #94012-5) diluted 1:4,000 
in PBS with 0,3% Triton X-100 and 1% bovine serum albumin. The primary antiserum was raised in 
rabbit against the N-terminal peptide similar to 2-17 of  the rat FOS protein and characterised previously 
(Mikkelsen et al., 1998b). The immunoreactive cells were identified by means of  the avidin-biotin 
protocol (Hsu and Raine, 1981) and diaminobenzidine was applied as chromogene as described by 
(Mikkelsen et al., 1998a). The sections were then mounted into 1% of  gelatine dissolved in 0.025M PBS, 
air-dried, coverslipped with Permount, and examined under 40 × objective light microscope. 
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3.7. DOUBLE LABELLING FOS / OXYTOCIN 
 
8 adult male NMRI mice weighing 30-35 grams were used for the C-FOS/oxytocin 
immunohistochemical studies. The animals were administered intraperitoneally with 12.5 mg/kg 
zolpidem, or vehicle (5% chremophor) at 4 hours after the onset of  the light phase and returned to their 
home cage. Sixty minutes after the injections the animals were deeply anesthetised with mebumal and 
perfused transcardially with 0.9% saline followed by 4% paraformaldehyde in 0.1M phosphate buffer (pH 
7.4) for 5 min. The brains were post-fixed over night in 4% paraformaldehyde and subsequently 
submerged in 20% sucrose in 0,01M buffered saline (PBS) at 4 ºC overnight. 40 μm serial coronal 
sections were cut through the hypothalamus on a freezing sledge microtome in series of  four and stored 
in a solution containing ethylene glycol glycerol in 30% sucrose at -20 ºC until further processing. 
 
Prior to the immunocytochemical steps, the sections were rinsed for 3 x 10 min in 0.01M PBS, in 1% 
H2O2–PBS for 10 minutes, and in PBS with 0.3% Triton X-100, 5% swine-serum, and 1% bovine serum 
albumin (BSA) for 30 min. Then the sections were incubated at 4°C for 24 hours in an antiserum against 
FOS (code #94012-5) diluted 1:4,000 in PBS with 0,3% Triton X-100 and and 1% bovine serum 
albumin. 
After several rinses in PBS, the sections were incubated with biotinylated goat-anti rabbit IgG (1:1000, 
VectorStain Elite ABC, Vector Lab., Burlingame, CA, USA) for 1 h at room temperature. Next, PBS 
rinsings were followed by incubation with the avidin–biotin peroxidase complex (1:500) for 1 h at room 
temperature. Intensive PBS washing was followed by washing in Tris HCL buffer (SAB, pH 7.4). Finally, 
the FOS antigenic sites were visualized by processing with TRIS HCL containing 0.0625% 3,3-
diaminobenzidine tetrahydrochloride (DAB, Sigma), 0.375% hydrogen peroxide, 3.0% nickel sulphate 
hexahydrate (Sigma), for 15–20 min. The heavy metal-intensification of  DAB produced black staining of  
the labelled nuclei. After several washings in PBS, the FOS-positive sections were incubated with 
oxytocin antibodies using the same procedure as described above. The oxytocin, (diluted 1:4000) 
immunoreactions were visualized in a DAB chromogen solution in Tris HCl (pH 7.4). To reach the 
appropriate light brown difference between the FOS and oxy-neuropeptide stainings, the developing time 
was monitored under the light microscope. Finally, the sections were mounted into 1% of  gelatine 
dissolved in 0.025M PBS, air-dried, coverslipped with Permount, and examined under a light microscope. 
 
3.8. DATA ANALYSIS  
3.8.1. FOS 
 
To quantify the effects of the benzodiazepine ligands tested, the slides were blinded, and the treatment was not 
revealed until all specimens had been counted. 
The number of positive cells was counted in each of the two paraventricular nuclei at its middle portion in the 
same tissue section cut at (bregma -1,40) according to the atlas of (Paxinos and Watson, 1997). The number of 
FOS expressing cells is given as the average of these two counts. 
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3.8.2. DOUBLE LABELLING FOS / OXYTOCIN  
 
The same blinding procedure was used as in the FOS study, in order to quantify the effect of the benzodiazepine 
ligands. The number of positive FOS, Oxytocin and double labelled FOS/oxytocin was counted each of the two 
paraventricular nuclei at its middle portion in the same tissue section. The number of FOS/Oxytocin reactive cells 
is given as the average of these two counts. 
 
 
3.9. RETROGRADE TRACING WITH CHOLERA TOXIN SUBUNIT B (CHB) 
 
Tracing using the retrograde tracer cholera toxin subunit B (ChB), was preformed in order to map the 
afferent connections of  the PVN, in this study rats was used over mice, because of  the larger brain, 
which gives a higher resolution when mapping neurocircuits. It is also much easier to make stereotactic 
injections in the rat compared to the mouse. 
Cholera toxin subunit B (ChB) was purchased from (List biological), 30 adult male wistar rats breed by 
the Panum animal facility weighing between 180–250 gram were housed two animals per cage under 
12:12 light: dark cycle, humidity in a temperature controlled room for at least 7 days before the 
experiment.  
The animals were anesthetized using a combination of  (fentanyl / fluanisone) 100 mg/kg mixed by the 
Panum animal facility. The animals were placed in a stereotaxic frame se figure 21. After having drilled an 
appropriate hole in the rat’s skull, one glass capillary microelectrode having a tip diameter less than 25 μm 
was filled with the solution of  ChB using a Hamilton micro pipette and inserted into the region of  the 
PVN. Coordinates were  -1.4 mm caudal and -0.5 mm lateral to the bregma, and -7.6 mm below the dura, 
according to the atlas of  (Paxinos and Watson, 1997) ChB was injected iontophoretically by applying a 
pulsatile current of  10 pA (0.5 seconds on; 0.5 seconds off) for 5-10 minutes. 
 
Figure 22 shows a wistar male rat mounted on a stereotaxic frame  
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After a survival period of  7 days the animals were re-anesthetized with mebumal and perfused 
transcardially, as described above. Immunohistochemical visualization of  ChB was carried out on free-
floating 40 μm sections cut in series of  6 from BNST through PVN, the sections were stored in a 
solution containing ethylene glycol glycerol in 30% sucrose at -20 ºC until further processing. The ChB 
tracer was visualised using a primary goat antibody from List Biological inc., the visualisation protocol 
was carried out using the avidin-biotin protocol as described for the FOS study in section (5.3.). Finally, 
the sections were mounted in 1% gelatine dissolved in 0.025M PBS, air-dried, coverslipped with 
Permount. and examined under a light microscope. 
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3.9.1. STATUS CHB INJECTED ANIMALS  
 
A number of animals were selected for further investigations this was done on the basis of the results achieved in 
the single ChB labelling. The animals were selected on the basis of the position of the injections site.   
 
Identification number Position of injection site Further analysis  
A138 No hit  No further analysis  
A139 Sub PVN No further analysis  
A140 PVN dorsal, caudal hit Analysis 
A141 No hit  No further analysis 
A142 PVN hit Analysis  
A143 No hit No further analysis 
A144 No hit No further analysis 
A145 No hit No further analysis 
A146 No hit No further analysis 
A147 PVN caudal hit Analysis  
A148 Sub PVN No further analysis 
A149 PVN caudal hit No further analysis 
A150 No hit  No further analysis 
A151 Direct PVN Hit  Analysis 
A152 No hit No further analysis 
A153 euthanatized No further analysis 
A201 No hit No further analysis 
A202 euthanatized No further analysis 
A203 No hit No further analysis 
A204 euthanatized No further analysis 
A205 No hit No further analysis 
A206 No hit No further analysis 
A207 Weak dorsal rostral hit No further analysis 
A208 No hit No further analysis 
A209 No hit No further analysis 
A210 No hit No further analysis 
A211 euthanatized No further analysis 
A212 No hit No further analysis 
A213 No hit No further analysis 
Table 1 list the number of rates used in the ChB retrograde neuro-tracing studies, the animals selected for further investigations were chosen 
on the basis of the results archived in the single ICC (immunocytochemistry) of ChB. 4 animals were in such a condition after the operation 
that they had to be euthanatized before they could be perfused and could therefore not be used for ICC.     
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3.10. IN SITU HYBRIDIZATION, LOCATING THE ANATOMICAL DISTRIBUTION OF 
THE GABAA α1, α2 AND α3 SUBUNITS.  
 
 
10 naïve male wistar rats weighing 180-220 g were decapitated and the brains rapidly removed, frozen on 
dry ice and stored at -80ºC.  
Brains were cut through the PVN using a Leica cryostat CM3050, and a series of  twenty 12 μM thick 
coronal sections were obtained and subsequently mounted on Superfrost Plus slides (VWR International 
ApS, Albertslund, Denmark).  
In situ hybridization was performed using S35 labelled RNA probes, directed against the GABAA α1, α2 
and α3 subunits (see appendix D for details). The hybridization was kindly performed by technician  Pia 
Rovsing Sandholm according to a protocol previously described by (Bomholt et al., 2005; Mikkelsen and 
Larsen, 1993) 
 
For each brain, a total of  twenty sections were obtained, Slides were allowed to dry and stored at -80 C 
until in situ hybridisation (ISH) experiments were performed using one series of  sections for 
hybridization of  each transcript. 
After in situ hybridization, the sections were then exposed to an x-ray film for 3 weeks and analysed using 
a standard light table. 
For additional cellular localisation of  GABAA α1, α2 and α3 mRNA, the slides were subsequently dipped 
in nuclear emulsion (Ilford Imaging UK Ltd, Cheshire, UK) and exposed for 4 week. In order to 
distinguish the anatomical boundaries the sections were thionin counterstained according to the protocol 
described by (Wittekind et al., 1979), and analysis of  GABAA transcript in the PVN, SubPVN and in the 
was examined using a  60 ×  light microscope with a bright field condenser. All analysis and development 
using nuclear emulation was performed by myself.   
 
 
 
GABA NEUROCIRCUITS CONTROLLING  
THE HYPOTHALAMIC-PITUITARY-ADRENAL AXIS 
 
                          
 
− 34 − 
JANUARY 2006 
NeuroSearch 
3.11. IN SITU HYBRIDIZATION FOLLOWED BY IMMUNOCYTOCHEMISTRY 
(CONDUCTED AT THE GENOME RESEARCH INSTITUTE, UNIVERSITY OF 
CINCINNATI) 
 
3.11.1. PROBE PREPARATION PROTOCOL 
 
The following procedure is to my best knowledge novel, and has not been previously described, using free floating 
sections. 
 
Antisense rat GAD65 probe was produced by in vitro transcription using [35S] UTP. Plasmids containing the 
GAD65 inserts (Courtesy of J.P Herman, University of Cincinnati) were linearized with restriction enzyme StuI and 
transcribed using T3 RNA polymerase. 
 
The following was mixed in an Rnase-free 1.5 µl screw-top eppendorf tube:  
 
3.0 µl 5× transcription buffer  
1.0 µl 1,0 M DTT 
1.5 µl 10 M NTP Mix  
2.5 µg linearized GAD65 dissolved in 2.5 µl DEPC H2O  
1.0 µl DEPC treatet water  
5.0 µl 35S UTP 
 
The mixture was incubated for 1 hour at 37 ºC, then 2.0 µl of Dnase was added followed by an additional 15 min 
incubation at 37 ºC. The mixture was removed from the incubation oven and 4.0 µl of tRNA (15mg/ml) was 
added and was allowed to sit for 10 minutes at room temperature (RT) then an additional 79 µl of DEPC H2O and 
50 µl (7.5M) NH4Ac was added. 
The mixture was resuspended in 350 µl of 100% cold ethanol and stored at -80ºC for 1 hour for ethanol 
precipitation.  
The mixture was spun in a micro centrifuge (12000 RPM) for 20 minutes at 4ºC, the ethanol was aspired and the 
resulting pellet was allowed to dry. The pellet was then resuspended in 100 µl of DEPC treated water. 1 µl was 
removed and the activity counted using a scintillation counter.   
 
3.11.2. IN SITU HYBRIDIZATION FOLLOWED BY IMMUNOCYTOCHEMICAL STAINING  
 
Day 1: A Series of tissue sections from the ChB treated animals were taken from the -20°C freezer, and transferred 
to 6 well culture plates from PGC Scientific.  Sections were rinsed twice in 50mM potassium PBS (KPBS) for 5× 5 
min, sections were then incubated in blocking buffer (50mM KPBS, 0.3% TX-100, 0.2 % BSA) for 30 minutes. 
The sections were then incubated in the hybridization solution (see appendix d) overnight at 37 ºC in a 
hybridization oven.  
 
Day 2: The sections were rinsed 2×10 minutes in 2 × SCC at RT, they were then incubated in RNAse A (200 
µg/ml) in RNAse buffer 3 hrs at 37 ºC. Next the sections were rinsed in 2×SCC, 1×SCC  0,5×SCC for 10 minutes 
at RT, and then transferred to blocking buffer and incubated for 1 hour at 45 ºC the sections were next incubated 
overnight at 4 ºC in blocking buffer with  primary anti sera: anti cholera toxin B raised in goat diluted 1:6000.  
 
Day 3: The sections were rinsed in 50mM KPBS containing 0.02% TX-100 for 5×5 minutes RT, then the sections 
were incubated in biotinylated secondary antibody (donkey anti goat)  in 50mM KPBS + 0.02 %  Tx-100 for 1 
hour at RT. Next the tissue was rinsed 5×5 minutes in 50 m KPBS containing 0.02 % Tx-100 at RT, and incubated 
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in ABC solution at 1:500 in 50mM KPBS +0.1 BSA for 1 hour at RT. The sections were then rinsed for 5×5 
minutes in 50mM KPBS + 0.02% Tx-100 at RT. 
ChB staining was visualized using TRIS HCL containing 0.0625% 3.3-diaminobenzidine tetrahydrochloride (DAB, 
Sigma), 0.375% hydrogen peroxide. 
 
The sections were then mounted in 1% gelatine dissolved in 50mM KPB, and air-dried. In order to verify the 
GAD65 hybridization the glass slides were exposed on a phosphor screen for 3 days, the film was developed using a 
storm dynamics Model 400E Phosphorimager. After having verified, that the GAD65 hybridization had been 
successful, and that the glass slides were subsequential, under dark room conditions the slides were dipped in 
Kodak Ntb nuclear emulsion and left to expose for at total of 30 days.     
At the end of the 30 days the emulsion was developed using KODAK D-19 Developer and KODAK Fixer. Then 
the glass slides were coverslipped with DPX mounting solution, and examined under a light microscope. 
 
3.12. ELECTRONIC PICTURE PROCESSING  
 
All pictures were taken using a standard light microscope, with a digital camera attached. The following levels of 
magnification were available: 5 ×, 10 ×, 20 ×, 40 ×, 60 × (×=102).  All pictures taken with 20 × or higher were 
taken using a bright field or dark field condenser.  
The digital pictures were saved to a local computer as high resolution TIFF files. Most pictures used in this rapport 
were processed using Adobe Photoshop 8.0. This was done by adjusting, colour or contrast in order to achieve the 
best illustrations possible.      
 
3.13. STATISTICS  
 
The standard error on the graphs in the following chapters is presented with standard error mean (SEM) this has 
been calculated as standard deviation divided by the square root of the sample size (n). 
.Std Error
n
. 
The difference between groups in the following chapters has been measured using Analysis of Variance ANOVA. 
The rational being, that a factorial ANOVA can examine data that are classified on multiple independent variables. 
For example, a two-way ANOVA (two factors ANOVA) can measure both the difference among treatments and 
among groups simultaneously. You can use more than two independent variables. A factorial ANOVA can show 
whether there are significant main effects of the independent variables, and whether there are significant interaction 
effects between independent variables in a set of data. Interaction effects occur when the impact of one 
independent variable depends on the level of the second independent variable. A crucial component when using 
ANOVA is that your data are normalized and fitting a bell shaped curve, when this has not been the case, the data 
have been log transformed in order to normalize it. 
All calculations has been done using SigmaStat computational software from SysStat software inc. 
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4. RESULTS  
 
4.1. EFFECT OF ACUTE TREATMENT WITH BENZODIAZEPINES / GABAA 
POSITIVE MODULATORS. 
 
Figure 23 Time course profile of ACTH and corticosterone responses to a single dose of zolpidem (12,5 mg/kg) in mice  (n = 5). The figure 
illustrates the relative rise of plasma ACTH (open circles) and corticosterone (closed circles) levels at various time points after zolpidem. The 
time course illustrates that release of ACTH occurs immediately after administration of zolpidem and that it precedes the release of 
corticosterone. 
 
Figure 23 shows ACTH and corticosterone responses after acute administration of zolpidem. Zolpidem 
significantly and dose-dependently stimulated the peripheral components of the mouse HPA axis. Plasma ACTH 
was found to be about 15-fold above baseline levels and corticosterone increased about 10-fold. The time course 
illustrates a significant effect of zolpidem on ACTH release within 5 min after administration which reached its 
maximal level at 10 min. Thereafter the ACTH level declined over time and reached basal levels after 120 min (Fig. 
23). The time course for corticosterone was slightly delayed compared to ACTH, peaked about 60 min after 
zolpidem and returned to baseline after 120 min. 
This indicates that the peripheral components of the HPA axis are activated almost solely through the release of 
ACTH from the pituitary, and not through direct input from the sympathetic nervous system to the adrenal cortex. 
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Figure 24 The effect of increasing doses of the non-selective benzodiazepine ligands diazepam (closed squares) and zopiclone (closed 
triangles) on plasma corticosterone levels in mice compared to the α1 selective zolpidem (closed circles) and the α2,3 selective agonist L-
838,417 (open circles). The four drugs are given as a single dose and the mice are sacrificed 60 min after the treatment. The data represent 
mean ± S.E.M. of minimum 5 mice per group. There was a significant (p < 0.05) difference between the effect of non-selective and selective 
benzodiazepine receptor ligands. #p < 0.05 vs zolpidem and *p < 0.05 vs vehicle. Two-way ANOVA and Student-Newman-Keuls test.  
 
 
It is demonstrated that the rise in plasma corticosterone is drug and dose dependent. Treatment with zolpidem 
which is an α1 selective agonist increased plasma corticosterone at a minimum effective dose of 0.5 mg/kg reaching 
a maximum at 12.5 mg/kg. Zolpidem was effective and increased circulating corticosterone up to about 800 
ng/ml. (see figure 24). 
The potencies and efficacies of diazepam and zopiclone were significantly lower than for zolpidem (Fig. 24). Thus, 
a rise in plasma corticosterone was seen after 2.5 mg/kg and the maximal level of corticosterone was in the range 
of 400 ng/ml. 
Notably, while zolpidem induced a slightly higher level of corticosterone at 25 mg/kg compared to 12.5 mg/kg, the 
two non-selective benzodiazepine ligands produced a slightly lower level of corticosterone. The two non-selective 
benzodiazepine ligands produced a different dose-response curve with zopiclone being slightly stronger than 
diazepam.  
The α2,3,5 selective agonist L-838,417 was ineffective in activating the peripheral component of the mouse HPA axis 
at up to 25 mg/kg where nonspecific effects probably did induce a slight stress hormone response.  
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4.2. INTERACTION INHIBITION STUDIES  
 
In order to investigate the relationship between activation of α1 and non– α1 containing GABAA receptors, 
combinations of L-838,417 (12.5 mg/kg i.p.) or vehicle was given 15 min before a single dose of zolpidem i.p at 
increasing concentrations (0.5, 2.5, and 12.5 mg/kg) L-838,417 clearly inhibited the effect of zolpidem at all doses 
(see figure 25). 
In order to determine that the inhibitory action of L-838,417 is not solely due to the compound’s antagonistic 
properties at the GABAA α1 receptor, a combination of the two non-selective benzodiazepine ligands diazepam and 
zopiclone was tested together with zolpidem. In this case mice were treated with vehicle, diazepam (0.5 mg/kg i.p.) 
or zopiclone (0.5 mg/kg i.p.), 15 min before administering the mice with 0.5 mg/kg zolpidem (see figure 26) or 2.5 
mg/kg zolpidem (see figure 26). The animals were sacrificed 60 min after zolpidem administration and trunk blood 
was taken for corticosterone measurements. All single and combined dosing experiments were carried out twice. At 
0.5 mg/kg diazepam or zopiclone before 0.5 mg/kg zolpidem, both diazepam and zopiclone inhibited the effect of 
zolpidem, although diazepam was more potent than zopiclone. Neither diazepam nor zopiclone were able to 
inhibit the effect of 2.5 mg/kg zolpidem (see figure 27).  
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Figure 25  The animals pre-treated with vehicle followed by Zolpidem are shown as closed circles and the animals pre-treated with  L-
838,417 are shown as open circles. The values are given as mean (n = 5) ± SEM. Significance between groups was determined by two-way 
ANOVA and **p < 0.01. Two-way ANOVA and Student-Newman-Keuls test 
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Figure 26 Pre-treatment with 0.5 mg/kg diazepam, zopiclone or 12.5 mg/kg L838,417 15 min before administration of 0.5 mg/kg zolpidem 
(all compounds were administered i.p.) inhibit release of corticosterone. As negative control mice were treated with vehicle twice, and as 
positive control zolpidem was administered 15 min after vehicle. ** p < 0.01; * p < 0.05 vs zolpidem. The data represent mean ± S.E.M. of 
minimum 5 mice per group. 
 
It is seen that pre-administration of both diazepam as well as zopiclone at a relatively low dose 0.5 mg/kg (i.p) 
significantly inhibits the effect of zolpidem, compared to animals pre-administered only with vehicle. At this dose 
of zolpidem, it seems that diazepam and to a lesser extent zopiclone is almost as effective as L-838,417 in inhibiting 
the effect of zolpidem on the murine HPA axis. 
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Figure 27  Pre-treatment with 0.5 mg/kg diazepam, zopiclone or 12.5 mg/kg L838,417 15 min before administration of of 2.5 mg/kg 
zolpidem does not inhibit the release of corticosterone compared to vehicle + zolpidem. L-838,417 still significantly inhibits the effect of 
zolpidem even at this high dose. As negative control mice were treated with vehicle twice, and as positive control zolpidem was 
administered 15 min after vehicle. ** p < 0.01 vs. zolpidem, Two-way ANOVA and Student-Newman-Keuls test . The data represent mean 
± S.E.M. of minimum 5 mice per group. 
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4.3. EFFECTS OF BENZODIAZEPINE LIGANDS ON THE INDUCTION OF FOS IN 
THE PARAVENTRICULAR NUCLEUS.   
 
 
Figure 28 shows the distribution of FOS in the paraventricular region in naive mice (A), and after administration with vehicle (B), L-838,417 
(C), zopiclone (D), diazepam (E), and zolpidem (F). All drugs are given in a dose of 12.5 mg/kg 60 min before sacrifice. Scale bar =100 μm. 
All pictures were taken using a digital camera mounted on a light microscope, at a 20 × resolution.  
 
4.4. EFFECTS OF BENZODIAZEPINE LIGANDS ON FOS EXPRESSION IN THE 
PARAVENTRICULAR NUCLEUS 
 
FOS induction was studied in male mice treated with zolpidem, L-838,417, zopiclone, or diazepam all at 12.5 mg pr 
kg i.p., as controls a number of vehicle treated animals were also investigated.  
Only a small number of FOS expressing cells was observed in the PVN of these control groups see (figure 28 A 
and B). As for zopiclone, diazepam and zolpidem all compounds produced a strong increase of FOS containing 
nuclei in the PVN. The activated cells were present in an area overlapping with the CRH containing medial 
parvocellular subportion of the paraventricular nucleus (Kiss, 1988), but also in the magnocellular portion of 
nucleus, se figure 28.  
L-838,417 did not produce any FOS response in the treated animals compared to vehicle, furthermore diazepam 
produced a significantly lower response compared to that of zolpidem. This finding corresponds well to the data 
observed on the peripheral components of the HPA axis (corticosterone data shown in figure 24). 
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Figure 29 Quantitative analysis of FOS expression in the paraventricular nucleus after acute treatment with benzodiazepine ligands. The 
effect of FOS induction was analysed 60 min after single administration of drugs at 12.5mg/kg i.p., the same dose that produces a maximal 
increase of corticosterone in plasma. The values are given as the mean number of cells expressing FOS in one section of the middle part of 
the paraventricular nucleus (mean-±S.E.M.). ***P <0.001; *P <0.05 compared to zolpidem. ANOVA nonparametric Tukey’s multiple 
comparison test. 
 
Figure 29 clearly show that zolpidem, diazepam and zopiclone all induce FOS in the PVN while there is no 
induction after vehicle and L-838,417. 
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4.5. IDENTIFYING FOS EXPRESSING NEURONS IN THE PVN  
 
An effort was made to investigate whether the FOS stained neurons in the PVN was co-localized with the  
oxytocin producing neurons (Wotjak et al., 2001). 
This was done using a double immunocytochemical protocol with nickel enhancement as described in section 
(9.4.). 
 
 
FOS positive cell 
Oxytocin stained 
cell 
Figure 30 Shows a 40 μm section of the lateral part of the PVN cut at bregma (-1,40)  from a male NMRI mouse treated with 12,5 mg/kg 
zolpidem 1 hour before sacrifice.   The slide has been stained for FOS using nickel enhancement and for Oxytocin using a standard ABC, 
DAB protocol, as described in section 3.8.2. 
 
 
Figure 31 Dual-labeling for FOS and oxytocin; after administration of 12,5 mg/kg Zolpidem, or vehicle 1 hour before sacrifice.  The values 
are given as the mean number of cells expressing FOS, oxytocin or co-localization in the middle part of the paraventricular nucleus (mean-
±S.E.M.). of minimum 8 mice per group. All brain sections were counted using a light microscope with a bright field condenser, FOS and 
oxytocin and FOS/oxytocin was distinguished due to the colour difference achieved during immunocytochemistry.  
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Figure 31 shows that there seem to be no significant co-localization between oxytocin and FOS in the animals that were treated with 12.5 
mg/kg zolpidem.  
 
4.6. RESULTS FROM IN SITU HYBRIDIZATION  
 
In situ hybridization using radioactive probes directed against the GABAA α1 α2 and α3 was performed on 12 μm 
sections cut through the PVN as described in section 3.10.  
It would be out of the scope of this project to make a detailed map of the global distribution of the different 
GABAA subunits, for review see (Fritschy and Mohler, 1995), and the following sections will therefore only 
concentrate on the PVN and SubPVN area. 
 
 
 
   
A B C 
  α1   α2   α3  
 
Figure 32 All tissue sections are from mice and are cut at the level of the PVN (bregma -1.40 mm). (A) shows a picture of the distribution of 
radioactive labelled GABAA α1 m-RNA in the PVN, as it is seen; there is a very limited amount of α1 m-RNA expression in the direct 
surrounding of the PVN, while there is a very heavy staining in the cortex and the BNST. (B) Shows the distribution of the GABAA α2 
receptor in the PVN, It is clearly seen that there is a very distinct and heavy staining in the medial parvocellular section of the PVN as 
indicated by the arrow. (C) Shows the distribution of the α3 subunit there is little or no distribution in the PVN but there is heavy staning in 
the amygdale as is indicated by the arrow.  
 
Although the pictures shown her have a relatively poor resolution, they still show that there is a very different 
distribution of the GABAA α1, α2 and α3 subunit in the different brain areas and it is clear that the only subunit that 
is expressed to any significant extent in the PVN itself, is the α2 while the α1 subunit is expressed manly in the 
limbic areas and the α3 in the amygdala.  
 
 
4.7. DETAILED ANALYSIS  
 
Analysis using standard x-ray film does not allow for a detailed cellular resolution after in situ hybridization, so for 
additional information on the cellular localisation of GABAA α1, α2 and α3 mRNA, tissue sections were 
subsequently dipped in nuclear emulsion as described in section 3.10. 
The sections were then thionin counterstained and analysis of GABAA transcript in the PVN and SubPVN area 
was examined using a light microscope 60 × objective with and a bright field condenser.  
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4.8. GABAA  ALPHA 1 DISTRIBUTION IN THE PVN AND SUBPVN AREA 
 
 
   
1 2 3
A 
B 
Figure 33 (1) is a 10 × magnificationof the PVN of a naïve wistar rat cut at (bregma -1.40 mm).  The slide has been treated with a probe 
directed at the GABAA α1 subunit and dipped in nuclear emulsion, before counter staining with thionin.  The PVN borders has been drawn 
using Adobe Photoshop , and area A and B represent respectively the medial parvocellular part of the PVN, and the sub paraventricular 
area. (2) Shows a 60 × picture of area A from 33 (1), the black spots represents labelled GABAA α1 m-RNA. It seen that there is a very 
limited amount of black spots, and that the ones that are present seems dispersed and not located over the thionin stained neurons. Figure 
33 (3) shows a 60 × picture of area B from figure 32(1), the black spots represents labelled GABAA α1 M-RNA. It is seen that there is heavy 
staining located over the counter stained neurons. The arrows point to magnocellular neurons containing significant amounts of GABAA α1 
m-RNA. 
 
Figure 33 (1,2 and 3) shows that the PVN itself seems to be deprived of GABAA α1 expressing neurons while the 
immediate surroundings (the SubPVN) seems to be heavily innervated by neurons containing the α1 subunit. This 
is in good agreement with earlier observations reviewed by (Herman et al., 2002) that the PVN is surrounded by a 
GABAA “ring”, although the subunit composition of the GABAA receptor in the SubPVN area has not earlier been 
investigated.   
 
4.9. GABAA  ALPHA 2 DISTRIBUTION IN THE PVN AND SUBPVN AREA  
 
    
2 31 
A 
B 
Figure 34  is a10 × magnification of the PVN of a naïve wistar rat cut at (bregma -1.40 mm).  The slide has been treated with a probe 
directed at the GABAA α2 subunit and dipped in nuclear emulsion, before counter staining with thionin.  The PVN borders has been drawn 
using Adobe Photoshop, and area A and B represent respectively the medial parvocellular part of the PVN, and the sub paraventricular area. 
(2) Shows a 60 × picture of area A from 34 (1), the black spots represents labelled GABAA α2 m-RNA. It seen that there is a very intense 
staining over the magnocellular neurons in the PVN. Figure 34 (3) shows a 60 × picture of area B from figure 34(1) the black spots 
represents labelled GABAA α2 M-RNA. It is seen that there is no significant staining in the SubPVN section   
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Figures 32 through 34 shows that the medial part of the PVN seems to consist primarily of neurons that contain 
GABAA receptors with the α2 subtype, and the area surrounding the PVN (the SubPVN area) is populated by 
neurons containing the GABAA α1 subtype. 
  
4.10. GABAA  ALPHA 3 DISTRIBUTION IN THE PVN AND SUBPVN AREA  
 
The distribution of the GABAA α3 subunit was also investigated in the PVN and SubPVN area, α3 m-RNA did not 
seem to be distributed to any significant degree neither in the PVN nor in the SubPVN area, and the role of the α3 
subunit in the control of the PVN, can not be determined with the experimental data presented in this report. 
4.11. RESULTS FROM CHB RETROGRADE NEURO-TRACING.  
 
A total of 30 Wistar male rats were one hour before the tracing studies commenced injected with 10 mg/kg 
zolpidem i.p. They were then injected with ChB in the PVN as described in section 3.9. 
A total of 30 animals were used for the experiment, of these four died or had to be euthanatized before they could 
be perfused, due to post operative complications. 
The 26 remaining animals were all perfused transcardially. Then immunocytochemical visualization of ChB was 
carried out on free-floating 40 μm sections cut in series of 6 from BNST through PVN as described in section 3.9. 
Of the 26 animals that were examined, there were only two direct injection sites in the PVN, the remaining 
injections were located ether in the immediate surroundings of the PVN or in other hypothalamic regions, and in 
rare cases it did not seem like any ChB had been released at all (see table 1).  
The reason for the relatively low success rate can be ascribed to firstly the small size of the PVN, and secondly the 
fact that there is a diversity between individual Wistar male rats. The stereotaxic coordinates of the PVN are based 
on statistics and it is therefore not 100% useful when working with a outbred strain like Wistar (Paxinos and 
Watson, 1997). 
In the following section there will be a detailed analysis of one of the two animals, where we managed to put the 
glass electrode directly in to the PVN. The projections of the two were the same. Again it would be beyond the 
scope of this project to analyse all of the projections of the PVN, therefore it was chosen to focus on the bed 
nucleus of stria terminalis (BNST). BNST is part of the extended amygdala that is involved in the anxiety/stress 
response, and that has been the main reason for choosing this particular anatomical structure as an area of focus 
(Weller and Smith, 1982). 
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A B ChB hit in the PVN visualized by 
immunocytochemical 
stain 
   
C D 
Figure 35 A, B, C and D are all tissue sections from the same animal, A151 (see table 1). A shows a 4 × magnification of the injection site in 
the PVN, visualized by immunocytochemistry. The tissue is cut at (bregma 1,40) according to the atlas of  (Paxinos and Watson, 1997).  It is 
clearly seen that the ChB has been administered directly into the PVN. (B) and (C) shows the levels of the BNST the tissue has been cut at 
(bregma -2,12 mm) and (Bregma -0,26 mm) respectively it is seen that the BSTMA, BSTL and BSTMV all have numerous projections to the 
PVN. (D) Shows a 60 × magnification of the BSTMA area from figure 35 (B). 
 
A151 and A142 represent the only true PVN hits I was able to make, but it is also interesting to further investigate 
the hits in the immediate surroundings of the PVN. 
 
In order to investigate the projection of the BNST in detail the slides were investigated using a light microscope 
and a 60 × magnification. The stained neurons were then plotted using an electronic PDF version of the atlas of 
(Paxinos and Watson, 1997). It would serve no purpose showing pictures from all relevant areas therefore the 
following will only show selected pictures, and this only for the sake of illustration, since it is not possible to get 
microscope resolution using digital pictures. 
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A B 
 
C 
Figure 36: (A),(B) and (C) are schematic presentation of the pictures shown in figure 35, drawn in red is the most prominent projections in 
the area of which they occur, the schematic presentation is borrowed from the atlas of (Paxinos and Watson, 1997) and edited in Adobe 
Photoshop. (A) represents the injection site in the PVN, while (B) and (C) represents the neurons in the different levels of the BNST that 
project to the PVN. 
Figure 35 and 36 clearly shows that most of the BNST have neurons that project to the PVN. Although it seems 
like the BSTMA and BSTL are the areas that have the highest number of PVN projecting Neurons.  
The results from A151 (see figure 35) were the same as those found using A142, the data from A-142 is therefore not 
shown. This was the case even though the ChB injection in A-142 is more caudal than the hit in A-151. This 
indicates that the projections of the BNST are well disbursed through the entire PVN.   
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4.11.1. 6.11.1. PROJECTIONS OF THE BSNT TO THE SUBPVN AREA  
 
As described in the introduction to section (3.9) it was only possible to make 2 direct PVN hits with the ChB 
tracer. As a consequence of this, there were several “misses” that hit the areas in the vicinity of the PVN, some of 
these came very close and hit the SubPVN area (see area ”B” figure 34(1)). Since it seems that this area is of 
particular importance, when it comes to the control of the PVN, the following section will therefore deal with the 
BNST projection to the SubPVN area. 
 
  
A B 
 
C D 
Figure 37 (A) Shows a 4 × magnification of a SubPVN ChB injection, the tissue section is cut at (Bregma -2,12) according to the atlas of 
(Paxinos and Watson, 1997). This slide will hence forward be referred to as A-140 (se table 1). (B) Represents a schematic drawing of the 
injection site. (D) and (E) are schematic presentation of the projections from the BNST to the SubPVN. 
 
 
The data from the retrograde ChB tracing presented in figures 35 through 38 shows that the projections from the 
different anatomical sub nuclei of the BNST, to the PVN and SubPVN areas respectively are quite similal, and it 
seems that the projections of the BNST innervate these to area with almost equal intensity. Although not 
quantifiable with the present data, it does appear that while the BSTMV and BSTLP have numerous projections to 
the PVN, these areas only have a limited number of projections to the SubPVN area. While the BSTMA and the 
BSTL are saturated with neurons projecting to both the PVN and the SubPVN area.  
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4.12. DUAL IN SITU HYBRIDIZATION / IMMUNOCYTOCHEMICAL STAIN  
 
The purpose of this study was to identify which of the BNST, PVN projecting neurons are GABAergic, this was 
done by doing double labelling for ChB and GAD65, according to the protocol described in section 3.11. 
A number of sections from the different animals: A140, A142, A151 were used for the experiments (se table 1 for 
details). Unfortunately I did not succeed in performing successful combined staining with tissue from neither A142 
nor A151, which represented the animals with the best PVN hits. However I was successful in producing dual 
staining on tissue from A140 see (figure 37(A)). 
 
 
Figure 38 shows a 5 × magnification of A140, the section is cut at (bregma 0.20 mm) according to the atlas of (Paxinos and Watson, 1997) 
the black surface of the tissue is do to massive staining of the emulation by radioactive labelled GAD65 m-RNA. 
 
  
Figure 39 shows a 60 × magnification of dual ChB/GAD65 labelled cells in the BSTMA, the light brown cells are ChB positive cells and 
dark stains in the emulation is radioactive labelled GAD65 mRNA. The arrows indicate possible dual labelled cells.  
 
Figure 39 shows that there is a population of neurons in the BSTMA that has projection to the SubPVN. In this 
area there is also an intense GAD65 m-RNA labelling, making it highly feasible that the SubPVN projecting 
neurons in the BSTMA are GABAergic.  The BSTL also had projections to the SubPVN, but the GAD65 staining 
in this area was less intense than in the BSTMA. There was also some ChB staining in the BSTMV as shown in 
section 6.11.     
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Figure 40 shows a 40 × magnification of the BSTMA and BSTL from A140 using dark field filter. The Tissue section is cut at (bregma 0.20 
mm) according to the atlas of (Paxinos and Watson, 1997).  The white areas areas are areas with intense GAD65 labelling.  
 
Figure 40  is taken with a dark field filter using this filter it is clear to se that there is intense staining of radioactive 
labelled GAD64 in the BSTMA and BSTL, making a good case for the assumption that a large portion of the 
neurons in the BNST are GABAergic.     
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5. DISCUSSION  
 
Activation of the HPA axis due to external or internal challenges is important to the survival of species as well as 
the individual. Just as important as the stimulatory pathways are the inhibitory pathways, which limit the magnitude 
and duration of the stress response.  
The major mechanisms responsible for inhibition of stress are the steroid-dependent negative feedback via steroid 
receptors in the hippocampus and the direct neural inhibition of paraventricular nucleus neurons driven by the 
neurotransmitters GABA and substance P (Kovacs et al., 2004; Jessop et al., 2000).  
The fact that high doses of benzodiazepines stimulate the HPA axis was first shown in 1970s by (Havard et al., 
1972), this has since been rediscovered by numerous others (McElroy et al., 1987; Vargas et al., 2001) . 
But to date the seemingly controversial pharmacological mechanism by which this happens has not been clear. The 
data, presented in this thesis, show that acute administration of GABAA receptor subtype selective and non-
selective drugs have different effects on the murine HPA axis. 
The GABAA α1 selective agonist zolpidem induces a massive secretion of ACTH and corticosterone in the mouse 
both of these hormones are key components of the biological stress response (Jacobson, 2005). Zolpidem also 
upregulates the transcription factor FOS in the medial part of the PVN, this is a good indication that zolpidem 
exerts its effect at the level of the brain (Hoffman and Lyo, 2002).  
 
Administration of the two non selective benzodiazepine ligands diazepam and zopiclone also evoked a dose 
dependent corticosterone response, although to a lesser extent than zolpidem. The data obtained from 
administration of diazepam correlates well with those found in the literature (Vargas et al., 2001). Both of these 
compounds also induced FOS in the PVN.   
Meanwhile the GABAA α2,3,5 selective agonist and GABAA α1 antagonist L-838,417 (McKernan et al., 2000) was 
ineffective in activating a corticosterone response, the same was true with regard to a FOS response in the PVN. 
Pre-administration of L-838,417 15 minutes prior to a single dose of zolpidem clearly inhibits zolpidem’s effect on 
the murine HPA axis compared to animals treated with vehicle prior to zolpidem. This effect could in theory be 
ascribed to the fact that L-838,417 acts as an antagonist at the GABAA α1 receptor (McKernan et al., 2000). In 
order to test whether this was the case, we also pre-administered the animals with either of the two non-selective 
benzodiazepine ligands zopiclone or diazepam, prior to a single dose of zolpidem. Both diazepam and zopiclone 
inhibited the effect of zolpidem on the murine HPA axis, compared to vehicle followed by zolpidem. This 
indicates that the powerful inhibiting effect of L-838,417 is not solely due to the compound’s antagonistic 
properties at the GABAA α1 receptor.  
Since zolpidem is selective of the GABAA receptors containing the α1 over those containing the α2, α3 or α5 and 
zopiclone and diazepam are non-selective (Fleck, 2002; Pritchett and Seeburg, 1990), it might be proposed that that 
the α1 and non- α1 containing GABA neurons oppose each other in stimulating the CRH containing neurons of the 
paraventricular nucleus. 
It is most likely that the opposing GABAergic neurons in the PVN contain the α2 subunit, the rationale being that 
the α2 subunit is highly expressed in the CRH synthesising neurons in the PVN. This was verified using in situ 
hybridization, the same results have also been found by others (Wisden et al., 1992). This clearly indicates that the 
PVN itself is comprised of neurons with GABAA α2 surrounded by a “zone” of neurons with the GABAA α1 
receptor. That the PVN is surrounded by a zone of GABA neurons has been suggested earlier by (Cullinan, 2000; 
Pirker et al., 2000) although the GABAA α subunit composition of this zone has not been clarified before this.   
Since L-838,417 has almost equal affinity for the GABAA α2, α3 and α5,(McKernan et al., 2000) there is a theoretical 
possibility that the opposing neurons in the PVN could contain the α5 subunit. According to (Pirker et al., 2000; 
Fritschy and Mohler, 1995) the PVN does contain minute amounts of the α5 receptor shown by in situ 
hybridization and immunocytochemistry.  We have at our lab not been able to confirm this (data not shown), the 
same being the case for works published by (Cullinan, 2000). If α5 is present in the PVN both (Fritschy and 
Mohler, 1995; Pirker et al., 2000) agree that it is only in minute amounts compared to α2. This clearly supports the 
proposed mechanism in where the apposing neurons are of the GABAA α2 phenotype.    
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Figure 41 Schematic illustration of the model proposed for the action of selective and non-selective benzodiazepine 
ligands on the CRH neurons in the paraventricular nucleus. Non-selective benzodiazepine receptor ligands act on 
at least two different sites. One is outside the paraventricular nucleus and is disinhibiting the CRH neurons. The 
other is inside the nucleus leading to a direct inhibition of the HPA output. The balance between activation of 
these two targets determines the release or inhibition of stress hormone secretion to the blood.  
 
What the model suggests is that the CRH containing neurons in the PVN, that contain the α2 subunit, is under 
tonic inhibitory control from GABAA α1 neurons lying adjacent to the PVN, in the SubPVN. When the neurons in 
the SubPVN are inhibited with zolpidem, they are no longer able to exert their tonic inhibition of the neurons in 
the PVN. This creates a disinhibiting effect causing the CRH containing neurons in the PVN to depolarize. This is 
a possible explanation why high doses of benzodiazepines, causes the production of corticosterone in rodents and 
cortisol in humans.  
The setup presented in this thesis could also be used as an in vivo assay for a GABAA α2 effect, something that 
could be very useful during drug discovery; one example could be when searching for anti anxiety drugs 
(McKernan et al., 2000). 
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5.1. GABA NEUROCIRCUITS CONNECTING THE BED NUCLEUS STRIA 
TERMINALIS TO THE PARAVENTRICULAR NUCLEUS 
 
The BNST is part of the extended amygdala and is involved in anxiety and fear conditioned behaviours (Davis, 
1998a) this limbic forebrain structure links regions such as the amygdala and hippocampus with hypothalamic and 
brainstem regions and thereby controls vital homeostatic functions (Weller and Smith, 1982; Moga et al., 1989; 
Cullinan et al., 1993; Davis, 1998). It is therefore not surprising that this structure has numerous connections to the 
PVN.  
 
The attempt to map the afferent projections to the PVN, using the retrograde tracer ChB, verified what has been 
found by others, namely that the BNST has numerous projections to the PVN (Coolen and Wood, 1998; Davis 
and Shi, 1999). The results obtained show that much of the input to the PVN seem to originate in either in the 
BSTMA, BSTMV or the BSTL sub nuclei of the BNST. The fact that the BSTMA has projections to the PVN has 
previously been shown by (Okamura et al., 1990).  But that the BSTL and BSTMV also have projections to the 
PVN has to the best of my knowledge not previously been described. 
 
Using a novel histological method, an attempt was made to investigate whether the PVN projecting neurons in the 
BNST co-expressed GAD65. Unfortunately we ran out of tissue from the two animals with ChB injections directly 
into the PVN, so we only managed to do the dual in situ hybridization/immunocytochemical stain described in 
section 6.12. on an animal with a ChB injection in the SubPVN area. Using the tissue from this animal the only 
conclusive results that can be made, is that the BSTMA and the BSTL have neurons that seem to express massive 
amounts of GAD65 m-RNA, this correlates well with results from (Herman et al., 2002; Okamura et al., 1990) who 
also agree that a great number of the PVN projecting neurons in the BNST are GABAergic.  
The massive expression of GAD65 m-RNA in the BNST makes it close to impossible to tell whether  neurons are 
dual stained or not. With this in mind, it would be very interesting to do dual labelling for ChB and one of the 
GABAA α subunit, and in this way determine the subunit composition of the PVN projecting neurons in the 
BNST.  
  
5.2. METHODOLOGICAL CONSIDERATIONS   
5.2.1. FOS 
 
The choice of FOS as a marker of neuroactivity has been rationalized in section 3.6. And zolpidem, diazepam and 
zopiclone all induce FOS in the medial parvocellular part of the PVN, the activation of these neurons probably 
happen through an increase of intracellular cyclic AMP levels or activation of voltage sensitive calcium channels 
which lead to the phosphorylation of CREB and c-FOS induction (Thompson et al., 1995). This fits well with the 
fact that these CRH containing neurons have projections to the median eminence where they release CRH in to the 
hypothalamohypophyseal portal vascular system. CRH then stimulate the production of pituitary ACTH and the 
subsequent secretion of corticosterone from the adrenal cortex. 
There are other markers of  one could have considered some examples are c-jun, jun-B, jun-D that lie upstream 
from FOS (Curran and Franza, Jr., 1988a; Cohen et al., 1989), or Zif268 (Worley et al., 1991) but the fact that FOS 
is more often associated with depolarization makes it a superior marker, especially when working with 
neuroendocrine systems (Hoffman and Lyo, 2002). 
Yet another thing that could have been considered is in vitro electrophysical recording studies, where one could 
have used culture PVN slices, and in this way make direct electrophysical measurements after application of the 
different compounds used in this study. 
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5.2.2. DRUGS  
 
All drugs used except zopiclone and zolpidem were of the benzodiazepine family, the pharmacokinetics of a single 
dose of diazepam at 20 mg/kg i.p. show a Cmax after approximately 10 minutes. The serum concentrations then 
show a biexponential decline. The first rapid decline is characterized by a t½ (a) of 9.0 ± 2.1 min, the subsequent 
decline (b) is characterized by a t½ of 72.0 min ± 10.5 min (Walker et al., 1998). Zolpidem also reaches a Cmax 
within the first 15 minutes (Trenque et al., 1994),  zopiclone although structurally unrelated to the benzodiazepines 
do show similar pharmacokinetics (Goa and Heel, 1986b). Since L-838,417 belongs to the same chemical class as 
diazepam it is expected to show similar pharmacokinetics but this was not confirmed.   
The fact, that exact pharmacokinetic measurements were not conducted during the experiments, could 
pose a problem if we had done the corticosterone measurements in as shorter timeframe. But after 60 
minutes it is a reasonable assumption that all of the compounds have reached Cmax.. 
5.2.3. COMBINATION OF DRUGS 
 
It could easily be argued, that the mechanism by which L-838,417 inhibits the effect of zolpidem on the 
murine HPA axis, is simply due to L-838,417 antagonistic binding at the GABAA α1 receptors 
(McKernan et al., 2000). However diazepam and zopiclone which are both full agonist at the α1 receptor 
(McKernan et al., 2000; Sanger, 2004; Graham et al., 1996), for review see (Sieghart, 1995), at doses that 
do not themselves stimulate any significant corticosterone response, also inhibit the effect of zolpidem,  
making a strong case for the involvement of a non – α1 GABAA receptor.  
5.2.4. ANIMAL MODELS  
 
Adult NMRI male mice were used. Male mice were used in order to avoid any influence that the estrus cycle in 
females might have on the corticosterone levels. Also all experiments were carried out 4 hours after the onset of 
the light fase in order to avoid influence from the circadian rhythm that causes a natural variation in corticosterone 
during the day (Able, 2005).  
Whether or not the result can be transferred to higher mammals is hard to say. There is substantial proof in the 
literature that the HPA axis is a highly conserved mechanism among mammals (Orchinik, 2005; Kandel et al., 
2000).  And the fact that high doses of diazepam has been shown to increase basic levels of cortisol in human 
subjects (Havard et al., 1972), indicate that a similar mechanism might be at play in higher mammals including 
humans.  
5.2.5. IN SITU HYBRIDIZATION      
 
In situ hybridization was performed using radioactive antisense probes directed against the GABAA subunits α1, α2 
and α3.  in accordance with a protocol previously described by (Bomholt et al., 2005; Mikkelsen and Larsen, 1993).   
Although nuclear emulation enables the detection of mRNA at a cellular level, it is not readily quantifiable, which 
does pose a potential problem when comparing results from different brain areas. However the method is quite 
useful as a detection method, when proving that a particular gene is expressed in a certain area.   One could have 
measured the intensity of staining on the x-ray film (Matsuoka et al., 1992),  however this was not possible when 
working with very restricted anatomical areas  such as the SubPVN. But as seen with the α2 staining which were 
localized exactly in the PVN there was no difficulty determining that this particular subunit is expressed in high 
amounts in the PVN compared to other brain regions, and this has also been verified by others  
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5.2.6. RETROGRADE TRACING USING CHOLERA TOXIN SUBUNIT B (CHB)  
 
Even though the results achieved during the mapping of the afferent projections to the PVN, is in good agreement 
with those found in the literature (Herman et al., 2002; Okamura et al., 1990), there are several methodological 
concerns that need to be addressed when analysing the results.  
The first and primary concern is that ChB may not be a true retrograde tracer. During the immunohistochemical 
analysis of tissue from A142 and A151, the two animals with direct PVN injections, we found a small number of 
ChB positive cells in the median eminence. We know from the literature that the magnocellular CRH neurons in 
the PVN have several projections to the median eminence, and the median eminence does not have projections to 
the PVN (Herman et al., 2003; Larsen et al., 1994; Swanson and Sawchenko, 1980). This indicates that the ChB 
tracer may also to some degree be transported in an anterograde fashion, this of course dose pose some problems 
when mapping afferent neurocircuits. This could perhaps be helped by choosing a different tracer, for example is 
Flurogold (Nogueira et al., 2000; Ju et al., 1989). 
Another concern that need to bee addressed is leakages, during the retraction of the glass pipette from the PVN. 
During this retraction, a small amount of ChB leaked in to the tissue lying above the PVN, most probably the 
reuniens thalamic nucleus (Paxinos and Watson, 1997) this could give some false positive cells elsewhere in the 
brain. Again this is not very likely to be a problem due to the very small amount of leakage.  
 
5.2.7. DUAL IN SITU HYBRIDIZATION/IMMUNOCYTOCHEMICAL STAIN  
 
The method described in section 16.0. was used to identify neurons projecting to the PVN, that at the same time 
express GAD65.  
In the method two distinct techniques was combined namely immunocytochemistry and in situ hybridzation.  
The technique is quite useful and clearly holds great potential, there are however some concerns when working 
with this technique. One major concern is that the staining seen in the nuclear emulsion, actually lie in a layer above 
the cells, and not on the cells themselves, this makes it hard to identify double labelled cells with 100 % certainty.   
The specific probe used in this study the GAD65 probe, has a very high level of expression in the BNST, this makes 
it hard to identify if the GAD65 staining over the ChB immunolabelled cells actually originate from the ChB 
positive cells. One could solve this problem using a similar technique combining a fluorescent in situ hybridization 
with an immunoreaction for ChB, in this way both markers would physically be on the cell.   
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6. CONCLUSION 
 
 
It can be concluded that the different effects of benzodiazepines on the basal level of HPA activity in rodents are 
due to the basal difference between GABAA α1 and non-α1-dependent (presumably α2) modulation of the CRH 
neurons in the paraventricular nucleus and/or sub paraventricular area.  
 
It can be concluded that the corticosterone induction, produced by the compounds used in this study, with the 
outmost certainty has a central effect in the brain, and more specifically in the paraventricular nucleus of the 
hypothalamus. 
 
The results presented in this thesis does not conclusively determine what types of neurons are activated in the 
paraventricular nucleus after administration of zolpidem, however the preliminary results suggest, that the FOS 
expressing neurons does not co-express oxytocin. 
 
It can be concluded that the bed nucleus stria terminalis has several projections to the paraventricular nucleus and 
to the sub paraventricular area. It can also be concluded that the areas with the seemingly highest number of 
projections are the bed nucleus of the stria terminalis, medial division, anterior part and the bed nucleus of the stria 
terminalis, lateral division. This is however only an estimate. 
 
On the basis of the results presented in this thesis, it is not possible to determine if the PVN projecting neurons in 
the bed nucleus stria terminalis are GABAergic or not. The data do however show that the   
bed nucleus of the stria terminalis, medial division, anterior part and the bed nucleus of the stria terminalis, lateral 
division express high amounts of GAD65 making it highly likely that a large portion of the neurons in these 
anatomical subdivisions could be classified as being GABAergic. This however is not proof, that the neurons 
projecting to the PVN have the same phenotype.    
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8.1. APENDIX A (PREPARATION OF MEDIUMS, BUFFER AND SOLUTIONS: 
IMMUNOCYTOCHEMISTRY.) 
 
 
Cryoprotection solution 
 
1 L 
Glycerine   250 ml  
Ethylenglycol   250 ml  
PBS 0.1 M   500 ml  
Keep in refrigerator 
 
Phosphate Buffer Solution (PBS) 0.1 M  
 
• Acid solution:  
 
NaH2PO4-H2O   2.73 g  
NaCl    1.82 g  
Distilled water   200 ml 
 
• Alkaline solution:  
 
Na2HPO4-H2O   14.25 g  
NaCl    7.26 g  
Distilled water   800 ml  
 
Titrate the acid solution with with HCL or NaOH to reach pH 7.4 
Keep in refrigerator  
 
30 % Sucrose  
 
Sucrose  30 g  
PBS 0.1 M   100 ml 
Keep in refrigerator  
 
Tris-buffer (pH 7,4) 
 
Tris   12.1 g  
NaCl   17.5 g  
Milli Q-water  1910 ml  
1 N HCl  90 ml  
Keep in refrigerator  
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Gelatine 
 
Milli Q-vand    400 ml 
Gelatine  2 g  
Keep in refrigerator  
 
Blocking buffer 1 L 
 
Normal Swine serum   5 ml  
Bovine Serum Albumin (BSA) 1 g 
Triton 100 x (TX)  0.3 ml 
PBS    994.7 ml 
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8.2. APPENDIX B (PREPARATION OF MEDIUMS, BUFFER AND SOLUTIONS: IN 
SITU HYBRIDIZATION ) 
 
Preparation of mediums, buffer and solutions: In situ hybridization  
 
Hybridization solution  
 
5× hybridization stock    1.125 ml/well 
50 % dextran sulphate    1.125 ml/well 
Deionized formamide   2.8125 ml/well 
ssDNA     0.169 ml/well 
1 M DTT (Dithiothreito)  0,133 ml/well 
tRNA     0,056 ml/well 
Probe     4.5 million counts/well 
 
*This volume allows for 5 ml hybridization solution per well  
 
DEPC Water  
 
Mili-Q water     1 L 
DEPC (Diethylpyrocarbonate)  100 µl 
 
Incubate for 1 hour shaking the bottle every 30 minutes  
Store at room temperature.  
 
1.0 M DTT 
 
DTT (Dithiothreitol)   3.09 g  
Sodium acetate     20 ml  0,01 M pH 5,2  
Sterilize by filtration  
Store at -20 °C 
 
tRNA: 
 
tRNA (Boehringer Mannheim)  15 mg    
DEPC treated water    1 ml 
 
5 × hybridization stock: 10 ml  
 
1 M Tris-Hcl pH 7,5   1 ml 
0,5 M EDTA pH 8,0 in DEPC Water 100 µl 
100 × Denhardt’s (sigma aldric)  100 µl 
5 M NaCl in DEPC water  3.35 ml 
DEPC water     4.55 ml  
 
Keep in freezer 
 
ssDNA ( short strained DNA) 
 
Herring sperm (sigma aldric)  
  
20 × SCC (4L) 
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NaCl    701.2 g 
Sodium Citrate    352.8 g 
Mili-q water    3200 ml 
 
Adjust pH to 7,0 with NaOH  
Autoclave  
Store at room temperature  
 
 
RNase A 100 µg/ml  
 
NaCl    14,5 g 
Tris pH 8,0    0,69 g   
Rnase     50 µg 
Autoclaved mili-Q  500 ml 
 
Store in refrigerator 
 
K-PBS (50 mM) 
 
Mili-Q water   900 ml 
0,5 M KH2PO4 (monobasic) 20 ml 
0,5 M KH2PO4 (dibasic)  80 ml  
NaCl     9 g 
DEPC (Diethylpyrocarbonate) 100 µl 
  
1,0 M TEA (Triethanolamine) 
 
Triethanolamine   33.18 ml  
DEPC-treated water   150 ml   
 
Adjust pH to 8,0 with concentrated HCL, then bring up to 250 ml with DEPC water, and then autoclave before 
use. 
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8.3. APENDIX C SEQUENCE OF THE OLIGONUCLEOTID PROBES USED FOR IN 
SITU HYBRIDIZATION  
 
 
                           3       6      9      12    15       18     21    24     27    30     33     36     39     43     45 
GABAA α1: 5’ GTT GTT TTT ATT GAG AGG ATC CTT CAC TTT CTT TGG CTT TTC TGG 
                             
                            3       6      9      12    15       18     21     24     27       30     33     36      39      43    
GABAA α2: 5’ CAA CTT GGC TGG CCA CAC CAG GAG AAC AAG CAG CGG AAA CCA 
 
                            3       6      9      12    15       18     21     24     27       30     33     36     39     43 
GABAA α3: 5’ CAC TGT TGG AGT TGA AGA ACT GGG AGC AGC AGC CTT GGA CAT  
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8.4. APENDIX D (ABSTRACT PRESENTET AT THE SOCIETY FOR NEUROSCIENCE 
ANNUAL MEETING NOVEMBER 2005) 
 
Effects of  Benzodiazepines Receptor Agonists on the Hypothalamic-Pituitary 
Adrenocortical Axis 
 
ANDREAS SØDERMAN*, ALEXANDER KISS, NAHEED MIRZA, AND JENS D. MIKKELSEN 
 
Department of Functional Neuroanatomy and Biomarkers, and 3 Pharmacology, NeuroSearch A/S, Pederstrupvej 
93, 2750 Ballerup, Denmark 
Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia 
 
Previous studies have demonstrated that classical benzodiazepines decreases hypothalamic-pituitary-
adrenocortical cortex (HPA) axis activity. Paradoxically, high doses of  benzodiazepines also stimulate 
basal circulating corticosterone levels in some conditions. Because benzodiazepine agonists display little 
selectivity to any of  the α subtypes of  the GABAA receptor to which they bind, we propose that the 
unequivocal results are due to an α subtype-dependent modulation of  the HPA axis output. To test this, 
basal hormonal output and induction of  FOS in the hypothalamic paraventricular nucleus (PVN) were 
measured after administration of  various benzodiazepine ligands in mice. Zolpidem, a selective α1 
subtype agonist, produced a very strong increase in plasma ACTH and corticosterone whereas the inverse 
agonist FG7142 induced a small rise in plasma corticosterone. More surprisingly, the non-selective full 
agonists diazepam and zopiclone induced a lower increase in circulating corticosterone than after 
zolpidem. In contrast, the α2,3,5-selective benzodiazepine agonist and α1 antagonist  L-838,417 had no 
effect on corticosterone levels. Strong induction of  FOS in the PVN was found in response to zolpidem, 
diazepam, and zopiclone, but not after L-838,417. Finally, pre-administration of  L-838,417 prior to 
zolpidem strongly inhibited the effect of  zolpidem on corticosterone. Likewise, the non-selective agonists 
diazepam and zopiclone at a dose that alone had no effect on corticosterone also inhibited the effect of  
zolpidem. Taken together, these results suggest that benzodiazepine ligands modulate the HPA axis 
through partly opposite mechanisms; and that the net-effect is dependent on the composition of  the 
GABAA receptor subunits to which they bind.  
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Previous studies have demonstrated that classical benzodiazepines decrease hypothalamic–pituitary–adrenocortical cortex (HPA) axis
activity. Paradoxically, high doses of benzodiazepines also stimulate basal circulating corticosterone levels in some conditions. Because
benzodiazepine agonists display little selectivity to any of the a subtypes of the g-amino butyric acid (GABA)A receptor to which they bind,
we propose that the unequivocal results are due to an a subtype-dependent modulation of the hypothalamic–pituitary–adrenocortical cortex
axis output. To test this, basal hormonal output and induction of Fos in the hypothalamic paraventricular nucleus were measured after
administration of various benzodiazepine ligands in mice. Zolpidem, a selective a1 subtype agonist, produced a very strong increase in
plasma adrenocorticotropic hormone and corticosterone whereas the inverse agonist FG7142 induced a small rise in plasma corticosterone.
More surprisingly, the non-selective full agonists diazepam and zopiclone induced a lower increase in circulating corticosterone than after
zolpidem. In contrast, the a2,3,5-selective benzodiazepine agonist and a1 antagonist L-838,417 had no effect on corticosterone levels. Strong
induction of Fos in the paraventricular nucleus was found in response to zolpidem, diazepam, and zopiclone, but not after L-838,417. Finally,
pre-administration of L-838,417 prior to zolpidem strongly inhibited the effect of zolpidem on corticosterone. Likewise, the non-selective
agonists diazepam and zopiclone at a dose that alone had no effect on corticosterone also inhibited the effect of zolpidem. Taken together,
these results suggest that benzodiazepine ligands modulate the hypothalamic–pituitary–adrenocortical cortex axis through partly opposite
mechanisms; and that the net effect is dependent on the composition of the GABAA receptor subunits to which they bind.
D 2005 Published by Elsevier B.V.Keywords: ACTH (adrenocorticotropic hormone); Corticosterone; GABA; Paraventricular nucleus; Stress; L-838,417; Diazepam; Zolpidem; Zopiclone;
(Mouse)1. Introduction
GABA is the major inhibitory neurotransmitter in the
mammalian brain and the GABAA receptor is the site of
action of benzodiazepines. Multiple isoforms of GABAA
receptor exist; each receptor comprises of a pentameric
complex formed by the co-assembly of subunits selected
from 16 genes (a1–6, h1–3, g1–3, y, q, k, and u) surrounding a
central chloride ion-channel (Sieghart, 1995). Agonist0014-2999/$ - see front matter D 2005 Published by Elsevier B.V.
doi:10.1016/j.ejphar.2005.06.049
* Corresponding author. Tel.: +45 44608359; fax: +45 44608080.
E-mail address: JDM@Neurosearch.dk (J.D. Mikkelsen).activation of the GABAA receptor is augmented by the
anxiolytic benzodiazepine ligands, causing a parallel shift of
the GABA concentration–response curve (Barnard et al.,
1998; Sieghart, 1995). The a subunit isoform present within
an individual GABAA receptor subtype is the primary
determinant of benzodiazepine ligand recognition (Fleck,
2002; Mehta and Ticku, 1999; Pritchett and Seeburg, 1990).
GABAA containing a1, a2, a3, or a5 together with h, and a g2
subunit are all recognised by the classical benzodiazepines.
Other drugs distinguish the GABAA receptors on the basis of
their a subunit composition. For example, the sedative–
hypnotic imidazolpyridine zolpidem has higher affinity for
a1 than a2, a3, or a5 containing GABAA receptors (Squires etlogy 519 (2005) 223 – 230
J.D. Mikkelsen et al. / European Journal of Pharmacology 519 (2005) 223–230224al., 1979). More recently, compounds with subtype selection
for a2, a3, and a5 over a1 containing GABAA receptors such
as L-838,417 are considered to be involved in anxiolytic
properties (McKernan et al., 2000). It is therefore plausible
that distinct a subtype-specific GABAA receptors mediate
various effects of classical benzodiazepines.
Disturbances in the hypothalamic–pituitary–adrenocor-
tical (HPA) axis are well known in human depression and
anxiety, as well as in experimental animal models of anxiety
and depression (Arborelius et al., 1999; Holsboer, 2000;
Jensen et al., 2001; Van de Kar and Blair, 1999). The
abnormal hypersecretion of cortisol that occurs in a variety
of psychiatric disorders including major depression, sleep
disturbances, and anxiety is suppressed by administration of
benzodiazepines (De Boer et al., 1990). Neurons in the
medial parvocellular part of the hypothalamic paraventri-
cular nucleus contain corticotrophin-releasing hormone
(CRH), and these neurons integrate excitatory and inhibitory
signals and behavioural responses to stress into appropriate
secretion of CRH that leads to adrenocorticotropic hormone
(ACTH) release to the general circulation (Carrasco and Van
de Kar, 2003). GABA is essential as a negative regulator of
neuronal excitability in the paraventricular nucleus, thus
mediating the amplitude and the duration of the stress
response (Kovacs et al., 2004). GABA is also contained in
neurons comprised in the negative feedback loop to the
paraventricular nucleus (Bowers et al., 1998), and it is
plausible that GABAA receptors may act on converging
projections to the paraventricular nucleus. GABAergic
afferents in the paraventricular nucleus originating from a
number of forebrain areas have been reported and ultra-
structural studies have shown that GABAergic axons, to a
large extent, terminate on CRH neurons (Miklos and
Kovacs, 2002; Roland and Sawchenko, 1993), and in situ
hybridisation and in vitro autoradiography have detected a1,
a2, and a3 subtypes in the paraventricular nucleus (Cull-
inan, 2000; Duncan et al., 1995; Fenelon et al., 1995).
The role of benzodiazepines on basal corticosteroid
release is complex, and even though it has been extensively
studied over the last three decades, there is still a lot of
controversy in the literature. Benzodiazepines have, under
basal conditions, been shown to stimulate (Calogero et al.,
1990; Le Fur et al., 1979; Vargas et al., 2001), to inhibit
(Owens et al., 1989; Pivac and Pericic, 1993), and to be
ineffective (Matheson et al., 1988). The state of the animal
under which these drugs are tested should be considered
with special care, because benzodiazepines interact with
stress-related behaviours and cause a dose-dependent
inhibition of stress-induced rise in corticosteroid levels
(De Souza, 1990, for review). In addition, the effect of acute
benzodiazepines on basal corticosterone levels might be
related to several factors such as dose, compound and
gender of the animal (Wilson et al., 1996), and these
features might underlie the unequivocal results.
In agreement with the literature, we show here that doses
of diazepam higher than those producing anxiolytic effectsincrease corticosterone levels in the mouse blood (Kalman
et al., 1997; Lakic et al., 1986). We propose that the
conflicting results reported earlier may also be a conse-
quence of the net effect of non-selective benzodiazepines on
the various GABAA receptor a subtypes. In order to address
this issue, the responsiveness of the murine HPA axis output
was examined after acute and combined treatments with a
number of benzodiazepine receptor modulators specific for
the a1 and/or a2,3,5 containing GABAA receptors. In
addition, we used induction of Fos as a marker to identify
the level of activation in the paraventricular nucleus after
acute administration of benzodiazepine ligands.2. Materials and methods
2.1. Compounds
Zolpidem and zopiclone were purchased from Tocris Ltd.
(Bristol, UK). FG7142 (methyl-3-carboline-3-carboxamide), and
diazepam was purchased from Sigma-Aldrich (St. Louis, USA).
L-838,417 (7-tert-butyl-3-(2,5-difluoro-phenyl)-6-(2-methyl-2H-
[1,2,4]triazol-3-ylmethoxy)-[1,2,4]triazolo[4,3-b]pyridazine) was
synthesised by the Department of Medicinal Chemistry, Neuro-
Search A/S. All compounds were dissolved in 5% chremophor
and administered intraperitoneally at 10 ml/kg.
2.2. Animals and single administration of benzodiazepine ligands
Adult male NMRI mice weighing 30–35 g were purchased
from Harlan Inc (Hamburg, Germany). The animals were received
at the animal facility, and housed 5 per cage under 12:12-h light/
dark cycle, humidity in a temperature-controlled room for at least 7
days before the experiment. Food and water were available ad
libitum. All procedures were conducted in accordance with the
Danish National Guide for Care and Use of Laboratory animals. In
order to analyse the dose-dependent effect of all benzodiazepine
ligands on circulating corticosterone, mice (n =5) were adminis-
tered at doses 0, 025, 0.1, 0.5, 2.5, 12.5, and 25 mg/kg i.p. The
mice were returned to their home cages and sacrificed by
decapitation 60 min after drug administration. Trunk blood was
collected in centrifuge tubes containing 2 mg EDTA.
In order to examine the dynamics of the HPA axis, another
experiment was carried out to determine the temporal profile of
HPA activation by zolpidem. These mice were treated with 12.5
mg/kg zolpidem and the animals were sacrificed and trunk blood
was taken at various time points after drug administration (t =5, 10,
15, 30, 60, and 120 min). The blood was collected in EDTA
containing tubes, kept at 4 -C, and plasma was isolated by
centrifugation and stored at 20 -C until processed.
2.3. Combination of drugs
In order to investigate the relationship between activation of a1
and non-a1 containing GABAA receptors, combinations of L-
838,417 (12.5 mg/kg i.p.) or vehicle were given 15 min before a
single dose of zolpidem i.p. at increasing concentrations (0.5, 2.5,
and 12.5 mg/kg). L-838,417 acts at the benzodiazepine binding site
and is a functionally selective agonist at a2, a3, and a5 subtypes. In
addition, L-838,417 is an antagonist on the a1 site; it might be that
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Fig. 1. Time course profile of ACTH and corticosterone responses to a single
dose of zolpidem (12.5 mg/kg) in mice (n =5). The figure illustrates the
relative rise compared to naı¨ve animals of plasma ACTH (open circles) and
corticosterone (closed circles) levels at various time points after zolpidem.
The time course illustrates that release of ACTH occurs immediately after
administration of zolpidem and that precedes release of corticosterone.
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Fig. 2. The effect of increasing doses of the non-selective benzodiazepine
ligands diazepam (closed circles) and zopiclone (closed triangles) on
plasma corticosterone levels in mice compared to the a1 selective zolpidem
(open circles) and the a2,3 selective agonist L-838,417 (open triangles). The
four drugs are given as a single dose and the mice are sacrificed 60 min
after the treatment. The data represent meanTS.E.M. of minimum of 5 mice
per group. There was a significant ( P <0.05) difference between the effect
of non-selective and selective benzodiazepine receptor ligands. #P <0.05
vs. zolpidem and *P <0.05 vs. vehicle. Two-way ANOVA and Student–
Newman–Keuls test. The letters a and b denote a significant difference at a
given dose to either zolpidem (a) or L-838,417 (b).
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non-selective GABA potentiating benzodiazepine ligands, diaze-
pam and zopiclone, were tested together with zolpidem. In this case
mice were treated with vehicle, diazepam (0.5 mg/kg i.p.), or
zopiclone (0.5mg/kg i.p.) 15min before administering themicewith
0.5 mg/kg zolpidem. The animals were sacrificed 60 min after
zolpidem and trunk blood was taken for corticosterone measure-
ments. All single and combined dosing experiments were carried out
twice. ED50 values were calculated by non-linear regression using
GraphPad Prism software (version 2.01, Gradpad Software Inc., San
Diego, CA).
2.4. Radioimmunoassay
Plasma aliquots were stored at 20 -C until hormone levels
were determined. Plasma corticosterone and ACTH were measured
directly without prior extraction. In the case of corticosterone, it
was assayed using a commercial [125I] radioimmunoassay kit from
DPC Diagnostics. Plasma ACTH concentrations were determined
by a commercial radioimmunoassay kit from Amersham.
2.5. Immunohistochemistry for Fos
Sixty male mice were used for Fos studies. The animals were
administered i.p. with 12.5 mg/kg diazepam (n =9), zopiclone
(n =9), zolpidem (n =12), L-838,417 (n =9), or vehicle (5%
chremophor) (n =11) at 4 h after the onset of the light phase and
returned to their home cage. Sixty minutes after the injection the
animals were deeply anaesthetised with mebumal and perfused
transcardially with 0.9% saline followed by 4% paraformaldehyde
in 0.1 M phosphate buffer (pH 7.4) for 5 min. The brains were
post-fixed overnight and subsequently submerged in 20% sucrose
in 0.01 M phosphate-buffered saline (PBS) at 4 -C overnight.
Forty-micrometer serial coronal sections were cut through the
hypothalamus on a freezing sledge microtome in series of four and
stored in a solution containing ethylene glycol glycerol in 30%
sucrose at 20 -C until further processing. Prior to the
immunocytochemical steps, the sections were rinsed for 310
min in 0.01 M PBS, in 1% H2O2–PBS for 10 min, and in PBS
with 0.3% Triton X-100, 5% swine-serum, and 1% bovine serum
albumin (BSA) for 30 min. Then the sections were incubated at 4-C for 24 h in an antiserum against Fos (code #94012-5) diluted
1:4000 in PBS with 0.3% Triton X-100 and 1% bovine serum
albumin. The primary antiserum was raised in rabbit against the N-
terminal peptide similar to 2–17 of the rat Fos protein and
characterised previously (Mikkelsen et al., 1998; Woldbye et al.,
1996). The immunoreactive cells were identified by means of the
avidin–biotin protocol and diaminobenzidine was applied as
chromogene as earlier described (Mikkelsen et al., 1998).
2.6. Quantifications and statistics
To quantify the effects of the benzodiazepine ligands tested, an
observer blind to the treatment of the animals counted the number
of positive cells in each of the two paraventricular nuclei at its
middle portion in the same tissue section. The number of positive
cells is given as the average of these two counts. The middle
portion of the paraventricular nucleus was delineated according to
Paxinos and Franklin (2004) to about 2.98 mm rostral to the
interaural line. The number of immunoreactive nuclei was counted
within the total paraventricular nucleus at this level including both
the magnocellular and the parvocellular subportions of the nucleus.
The data were analysed by one- or two-way analysis of variance
(ANOVA) followed by the Student–Newman–Keuls method. All
data are represented as group meansT standard error of mean
(S.E.M.), and levels at p <0.05 were considered significant.3. Results
3.1. ACTH and corticosterone responses after acute administration
of benzodiazepine ligands
Zolpidem significantly and dose-dependently stimulated the
mouse peripheral components of the HPA axis (Fig. 1). Plasma
ACTH was found to be about 15-fold above baseline levels and
Fig. 3. The effects of FG7142 (open circles) on plasma corticosterone
compared to zolpidem (closed circles). The compounds were given at 6
different doses 60 min before sacrifice. FG7142 significantly increased
corticosterone at doses of 12.5 mg/kg and higher (P <0.05). There was a
significant difference of FG7142 compared to zolpidem ( P <0.01). Two-
way ANOVA and Student–Newman–Keuls test.
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(Fig. 1) The time course illustrates a significant effect of zolpidem
on ACTH release within 5 min after administration and reached its
maximal level at 10 min. The level of plasma ACTH 15 min after
zolpidem was significantly higher than sham (zolpidem 332T70
pg/ml vs. sham 27.6T6.8 pg/ml). Thereafter the ACTH level
declined over time and reached basal levels after 120 min (Fig. 1).
The time course for corticosterone was slightly delayed compared
to ACTH, and peaked about 60 min after zolpidem, and returned to
baseline after 120 min.
Treatment with zolpidem increased plasma corticosterone at a
minimum effective dose of 0.5 mg/kg reaching a maximum at 12.5
mg/kg (Fig. 2). The ED50 was calculated to be 1.5 mg/kg.
Zolpidem was effective and increased the circulating cortico-Fig. 4. a1 receptor agonists induce Fos in the mouse paraventricular nucleus. Di
administration with vehicle (B), L-838,417 (C), zopiclone (D), diazepam (E), and
sacrifice. Scale bar=100 Am.sterone up to about 800 ng/ml, a higher level comparable to that
seen in restraint-stressed rats (Kalman et al., 1997). Both diazepam
and zopiclone also produced a rise in plasma corticosterone.
However, the potencies and efficacies of diazepam and zopiclone
were significantly lower than for zolpidem (Fig. 2). Thus, a rise in
plasma corticosterone was seen after administration of these drugs
at 2.5 mg/kg and the level of corticosterone at this dose was in the
range of 400 ng/ml at maximal concentrations (Fig. 2). Notably,
while zolpidem induced a slightly higher level of corticosterone at
25 mg/kg compared to 12.5 mg/kg, the two non-selective
benzodiazepine ligands produced a slightly lower level of cortico-
sterone (Fig. 2). The two non-selective benzodiazepine ligands
produced a different dose–response curve, with zopiclone being
slightly stronger than diazepam. The two drugs were found to be
equally effective on the release of corticosterone. Based on the
dose–response curves the ED50 were calculated to be 2.4 mg/kg
for zopiclone and 7.7 mg/kg for diazepam. In contrast, the a2,3,5
subtype-specific agonist L-838,417 was ineffective at all doses
tested and produced only an insignificant increase in cortico-
sterone levels at the highest dose of 25 mg/kg (Fig. 2). Statistical
analysis revealed that both diazepam and zopiclone produced
significantly stronger effects on circulating stress hormones than
L-838,417, but significantly lower effect than zolpidem.
Treatment with a single dose of the a1 inverse agonist FG7142
compared to zolpidem had relatively little effect on circulating
corticosterone (Fig. 3). A significant release of corticosterone was
only observed at doses of 12.5 and 25 mg/kg, but even at these
doses the effects on corticosterone were much lower than after
zolpidem (Fig. 3).
3.2. Effects of benzodiazepine ligands on Fos expression in the
paraventricular nucleus
In order to determine whether the effects of benzodiazepine
ligands occur at the level of the paraventricular nucleus and howstribution of Fos in the paraventricular region in naı¨ve mice (A), and afte
zolpidem (F). All drugs are given in a dose of 12.5 mg/kg 60 min beforer
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Fig. 7. Pre-treatment with diazepam or zopiclone (both 0.5 mg/kg) 15 min
before administration of 0.5 mg/kg zolpidem inhibited release of cortico-
sterone. As negative control mice were treated with vehicle twice, and as
positive control zolpidem was administered 15 min after vehicle.
**P <0.01; *P <0.05 vs. zolpidem.
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Fig. 5. Quantificative analysis of Fos expression in the paraventricular
nucleus after acute treatment with benzodiazepine ligands. The effect of Fos
induction was analysed 60 min after single administration of drugs at 12.5
mg/kg, the same dose that produces a maximal increase of corticosterone in
plasma. The values are given as the mean number of cells expressing Fos in
one section of the middle part of the paraventricular nucleus (mean-
TS.E.M.). ***P <0.001; *P <0.05 compared to zolpidem. ANOVA non-
parametric Tukey’s multiple comparison test.
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treated with zolpidem, diazepam, zopiclone, and L-838,417 (all
drugs 12.5 mg/kg i.p.). A small number of Fos-immunoreactive
nuclei were observed in the medial paraventricular nucleus in
naı¨ve and vehicle treated animals (Fig. 4A and B). Similarly, in
animals treated with L-838,417, a low number of Fos positive
cells were observed in the paraventricular nucleus (Fig. 4C).
Zolpidem, diazepam, and zopiclone produced a strong increase of
Fos containing nuclei in the paraventricular nucleus (Figs. 4D–F
and 5). The activated cells were present in an area overlapping
with the CRH containing medial parvocellular subportion of the
paraventricular nucleus, but also in the magnocellular portion of
nucleus (Fig. 4). Labelling was also found in the magnocellular
supraoptic nucleus (not shown). Quantitative measurements of the
number of Fos cells in the entire paraventricular nucleus revealed
a strong increase after all drugs tested except L-838,417, whichVeh 0.5 2.5 12.5
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Fig. 6. Release of corticosterone by zolpidem (closed circles) is inhibited
by pre-treatment with L-838,417 (open circles). Pre-administration of
L-838,417 (12.5 mg/kg) 15 min before one injection of increasing
concentrations of zolpidem shows that L-838,417 inhibits the activation
by zolpidem at all doses tested. The values are given as mean
(n =5)TS.E.M. Significance between groups was determined by two-
way ANOVA and **P <0.01.was found to be ineffective (Fig. 5). Furthermore, Fos induction
after diazepam was significantly lower at a concentration of 12.5
mg/kg, corresponding to the relative effect on corticosterone
levels (Fig. 2).
3.3. Interaction/inhibition studies
Administration of 12.5 mg/kg L-838,417 immediately before
zolpidem (0.5, 2.5, or 12.5 mg/kg) produced a strong inhibition of
the release of corticosterone at all doses of zolpidem (Fig. 6). The
maximal effects of the combined treatment of L-838,417 and
zolpidem were comparable to the maximal effect of the non-
selective benzodiazepines when given alone.
The level of corticosterone in mice pre-treated with 0.5 mg/kg
diazepam before zolpidem was significantly lower than after
vehicle at a dose of 0.5 mg/kg zolpidem (Fig. 7). Also, pre-
treatment with 0.5 mg/kg zopiclone significantly inhibited the
effect of zolpidem at the same dose (Fig. 7).4. Discussion
Activation of the HPA axis to threatening stressful
environmental stimuli is essential, but accurate inhibitory
mechanisms are equally required to limit the magnitude in
activation of autonomic, neuroendocrine, and behavioural
responses. The major mechanisms responsible for inhibition
of stress are the steroid-dependent negative feedback via
steroid receptors in the hippocampus and the direct neural
inhibition of paraventricular nucleus neurons driven by the
neurotransmitters GABA and substance P (Jessop et al.,
2000; Kovacs et al., 2004). Notably, part of the neuronal
inhibitory GABAergic input to the paraventricular nucleus
is a likely target of the corticoid-sensitive limbic forebrain
structures (Herman et al., 2003).
It has not been understood how anxiolytics like
benzodiazepines can activate the HPA axis in high concen-
trations, in particular whether it can be an effect independent
of the GABAA receptor. We show here that acute adminis-
tration of the GABAA receptor a1 subtype selective
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1 GABA
CRH1 GABA
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Fig. 8. Schematic illustration of the model proposed for the action of
selective and non-selective benzodiazepine ligands on the CRH neurons in
the paraventricular nucleus. Non-selective benzodiazepine receptor ligands
act on at least two different sites. One is outside the paraventricular nucleus
and is disinhibiting the CRH neurons. The other is inside the nucleus
leading to a direct inhibition of the HPA output. The balance between
activation of these two targets determines the release or inhibition of stress
hormone secretion to the blood.
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HPA axis in mice. Furthermore, it is shown that zolpidem
induces expression of the transcription factor Fos in the
medial part of the paraventricular nucleus, suggesting that
zolpidem is acting in the brain. Zolpidem stimulates rapidly
and robustly the secretion of both plasma ACTH and
corticosterone levels. The ED50 was found to be 1.5 mg/kg,
which is similar or lower than doses producing behavioural
effects. The maximal response reached a level that has
earlier been reported to occur in C57/B mice exposed to
restraint stress or forced swim (Droste et al., 2003). The
non-selective benzodiazepine site ligands, diazepam and
zopiclone, did not have the same maximal efficacy as
zolpidem on corticosterone levels. Finally, the a2,3,5
selective agonist L-838,417 was ineffective. Since zolpidem
is selective for GABAA receptor complexes that contain a1
subunits over those containing a2, a3, or a5 subunits, and
zopiclone and diazepam are non-selective (Fleck, 2002;
Pritchett and Seeburg, 1990), it is suggested that activation
of a1 and non-a1 containing GABAA receptors may oppose
each other in stimulating CRH neurons in the paraven-
tricular nucleus. We consider the a2 subunit the main a
subunit opposing this action because it is highly expressed
in all CRH synthesising neurons in the paraventricular
nucleus (Cullinan, 2000). In contrast, a3 subunit mRNA is
not expressed in the paraventricular nucleus and a5 subunit
mRNA expression is, to a great extent, limited to the
hippocampus (Tietz et al., 1999).
The proposed model illustrated in Fig. 8 illustrates that at
least two GABAA receptors bearing at least two distinct a
subunits are involved in the regulation of the HPA axis
output in vivo. Zolpidem activates the HPA axis by
inhibiting a GABAergic input onto CRH neurons. Several
lines of evidence support the presence of a disinhibiting
GABAergic afferent input to the paraventricular nucleus.
CRH neurons are under tonic inhibitory GABAergic
control, because systemic administration of the GABAA
receptor antagonist bicuculline both stimulates corticoster-
one secretion and mimics stress-induced ACTH release
(Ixart et al., 1983). Moreover, bicuculline administered
directly into the paraventricular nucleus induces a rapid
increase in plasma ACTH (Cole and Sawchenko, 2002), and
suppression of GABAergic transmission appears to play a
permissive role for inducing an increase in secretory activity
of CRH in organotypic cultures (Bartanusz et al., 2004).
Therefore, by disinhibiting the GABAergic input onto CRH
neurons, zolpidem effectively stimulates the HPA axis (Fig.
8). By contrast, direct inhibition of the paraventricular
nucleus likely via an a2 subunit containing GABAA
receptor expressed in CRH neurons inhibits the HPA axis.
Therefore, the balance between pharmacological activation
of a1 and a2 containing GABAA receptors determines the
response of benzodiazepine receptor ligands on the HPA
axis. This hypothetical relationship is demonstrated by the
antagonism of zolpidem-induced corticosterone release by
L-813,417 (Fig. 6). Since L-838,417 in addition to itsselective action on a2, a3, and a5 subunits is also an
antagonist at a1 receptors (McKernan et al., 2000), we
cannot exclude the possibility that a competition between
L838,417 and zolpidem at this receptor subtype explains our
findings. However, diazepam and zopiclone, both of which
are full agonists at a1 receptors (Sieghart, 1995) at doses
that do not themselves stimulate corticosterone release, also
inhibit zolpidem’s effect, emphasising the role of GABAA
receptors containing an a subunit distinct from a1.
There appeared to be a good correlation between the
relative rise in plasma corticosterone concentrations and the
number of Fos containing cells in the paraventricular
nucleus after administration of all drugs. However, this
does not mean that Fos induction is required to elicit a
hormone output. The Fos signal in the paraventricular
nucleus appears to be a good marker for neuronal
excitability, emphasising, as illustrated in Fig. 8, that the
net result of increased neuronal inhibition via activation of
a1 GABAA receptors outside the paraventricular nucleus is
an increased excitability inside the paraventricular nucleus.
It is unlikely that zolpidem acts directly on the CRH
neurons, but rather on an inhibitory interneuron. Light and
electron microscopic studies indicate that nearly half of the
synapses within the paraventricular nucleus are GABAergic
(Decavel and Van den Pol, 1990) and CRH neurons express
GABAA receptor a and h subunits (Cullinan, 2000). This
raises the question: What are the inhibitory neurons
innervating the paraventricular nucleus that is modified by
zolpidem? Anatomical and functional studies suggest that
sources of GABAergic inputs to the CRH neurons emanate
J.D. Mikkelsen et al. / European Journal of Pharmacology 519 (2005) 223–230 229from the bed nucleus of the stria terminals, and these
neurons might be the same as those converging the negative
steroid-dependent feedback to the paraventricular nucleus
(Herman and Cullinan, 1997). In addition, parvocellular
neurons in the medial paraventricular subdivision receive
synaptic inputs from neurons in the lateral and dorsal
hypothalamus and the suprachiasmatic nucleus, all of which
are considered to be GABAergic (Larsen et al., 1994;
Roland and Sawchenko, 1993; ter Horst and Luiten, 1986;
Vrang et al., 1995). Glutamate microstimulation of neurons
in the paraventricular nucleus shows that GABA producing
neurons are abundant in this region, particularly those in a
region ventrolateral to the nucleus (Boudaba et al., 1996).
The same population of GABAergic neurons, in addition to
those in the bed nucleus of the stria terminals, is considered
to be a part of the feedback inhibition to the paraventricular
nucleus, because the projections from the subiculum and
amygdala terminate rather around than inside the nucleus
(Canteras and Swanson, 1992; Herman and Cullinan, 1997;
Roland and Sawchenko, 1993). These GABAergic neurons
are the targets for zolpidem and remain to be established by
combining neural tracers and visualisation of a1 subunits.
The available evidence suggests that the GABAergic
neurons stimulated by stress are likely located in the
paraventricular nucleus or at least in its close vicinity
(Herman et al., 2003; Kovacs et al., 2004). It seems
therefore plausible that the GABAergic neurons activated
by stress are the same as those stimulated by benzodiazepine
ligands.
Significant effort has been given on developing drugs
which interact at the benzodiazepine recognition site but
which are devoid of some of the side effects, particularly in
the tolerance and withdrawal (Atack, 2003). Separation of
the a1-dependent effect from the other a subunits is an
important tool to select such new selective GABAA receptor
modulators. Thus, it is believed that development of a
subtype selective agents will provide better anxiolytics.
However, experimental models that can distinguish between
activities attributed to different a subtypes are required.
Therefore, the delineation of the inhibitory inputs to the
paraventricular nucleus that are modulated by the a1 subunit
activation may provide insight into the mechanisms of
selective GABAA receptor ligands. Previous studies have
shown that benzodiazepine receptor ligands including L-
838,417 inhibit the effects of various stressors (Le Fur et al.,
1979; McKernan et al., 2000; Yagi and Onaka, 1996), and
our data suggest that this action could be mediated at the
level of the paraventricular nucleus. The doses of L-838,417
and diazepam selected in the present study, exerting an
inhibitory effect on the HPA axis, correlate well with the
effective doses in models of anxiety (McKernan et al.,
2000). In line with the recent research emphasizing a role
for a2 GABAA receptors in mediating the anxiolytic effect
of benzodiazepines (Lo¨w et al., 2000; McKernan et al.,
2000; Rudolph et al., 1999), it is tempting to speculate that
a2 containing GABAA receptors in the paraventricularnucleus are important in this effect, and that this effect
represents a good and easy detectable biomarker for a2
subtype efficacy in vivo.
In summary, despite the fact that diazepam, zolpidem,
and zopiclone all stimulate a1 containing GABAA receptors,
their immediate effects on the HPA axis differ. We conclude
that the previous results reporting that various benzodiaze-
pines produce different effects on the basal level of HPA
activity in rodents are due to the balance between a1 and
non-a1-dependent (presumably a2) modulation of the CRH
neurons in the paraventricular nucleus.Acknowledgements
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